

**CURRICULUM VITAE**  
**LISA GEORGIANNE RIDER, M.D.**  
January 2017

**CURRENT POSITION**

Deputy Unit Chief, Environmental Autoimmunity Group, Clinical Research Branch,  
National Institute of Environmental Health Sciences (NIEHS),  
National Institutes of Health (NIH)  
CRC, Room 4-2352, 10 Center Drive, MSC 1301  
Bethesda, MD 20892-1301  
Phone: (301) 451-6272  
FAX: (301) 451-5588  
Email: [riderl@mail.nih.gov](mailto:riderl@mail.nih.gov)

**EDUCATION**

1983-1987            **M.D.**, Duke University School of Medicine, Durham, N.C.

1979-1983           **A.B.**, Duke University, Durham, N.C.  
Chemistry with Biochemical Specialization

1979                 **High School Diploma**, Ridge High School, Basking Ridge, NJ

**POST-GRADUATE TRAINING**

1991-1993           **Pediatric Rheumatology Fellow**, Children's Hospital National  
Medical Center, Washington, DC

1991- 1993           **Clinical Associate**, Laboratory of Chemical Immunology (Dr. Henry Metzger),  
Arthritis and Rheumatism Branch, National Institute of Arthritis and Musculoskeletal  
and Skin Diseases, National Institutes of Health, Bethesda, Maryland

1990- 1991           **Pediatric Rheumatology Fellow**, University of Washington, Children's  
Hospital and Medical Center, Seattle, WA

1987- 1990           **Internship/Residency in Pediatrics**, University of Washington, Children's  
Hospital and Medical Center, Seattle, WA

**PROFESSIONAL POSITIONS**

09/2003– Present    **Deputy Unit Chief**, Environmental Autoimmunity Group (EAG), Clinical Research  
Branch, National Institute of Environmental Health Sciences, National Institutes of  
Health, Bethesda, MD

01/2001–09/2003    **Senior Clinical Investigator and Medical Officer**, Environmental Autoimmunity  
Group (EAG), Office of Clinical Research, National Institute of Environmental Health

Sciences, National Institutes of Health, Bethesda, MD

09/1996 – 12/2000 **Medical Officer and Staff Scientist**, Division of Monoclonal Antibodies, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration, Bethesda, MD

09/1993 -09/1996 **Medical Officer**, Division of Cellular and Gene Therapies, CBER, FDA, Bethesda, MD

### **CLINICAL RESPONSIBILITIES AND HOSPITAL APPOINTMENTS**

2001 – present Senior Clinical Staff, NIEHS, National Institutes of Health, Bethesda, MD

04/ 2008 – present Attending Physician, Myositis Clinic, Division of Rheumatology, George Washington University (2 days/month)

12/ 2005 – 06/ 2007 Attending Physician, Rheumatology, Children's National Medical Center (1 day/month)

1994 – 08/ 2005 Attending Physician, Pediatric Rheumatology, Walter Reed Army Medical Center, Washington, DC (1 – 2 days/month)

10/ 1993 – 2001 Junior Clinical Staff, NIAMS, National Institutes of Health, Bethesda, MD

### **ACADEMIC APPOINTMENTS**

09/ 2008 –present **Clinical Professor**, Department of Medicine, George Washington University, Washington, DC

11/ 2010 – present **Adjunct Professor**, Department of Pediatrics, Uniformed Services University of Health Sciences (USUHS) Bethesda, MD

11/ 2002 – 10/ 2010 **Adjunct Associate Professor**, Department of Pediatrics, Uniformed Services University of Health Sciences (USUHS) Bethesda, MD

03/ 1994 - 11/ 2002 **Assistant Professor**, Department of Pediatrics, Uniformed Services University of Health Sciences, Bethesda, MD

07/ – 08/ 1993 **Acting Instructor**, Div. of Immunology/Rheumatology, Department of Pediatrics, University of Washington, Children's Hospital and Medical Center, Seattle, WA

### **US PUBLIC HEALTH SERVICE APPOINTMENTS**

Captain (7/05 – present); Permanent Captain (7/07 – present)

### **LICENSURE AND CERTIFICATION**

American Board of Pediatrics, Certification in Pediatric Rheumatology (1994 - 2001, recertified 2002 – 2008, Certificate No 000113; recertified 2009 – 2018, certificate No. 00113)

American Board of Pediatrics (1990, re-certified for 1998 - 2004, Certificate No. 045457)

FLEX (1987)

Maryland Medical License #D46950, 12/30/94 - present (expires 9/30/2017)

District of Columbia Medical License, #MD19164, 1991 - April, 1997;

# MD035811, 10/27/2005 – 12/31/2016

Virginia Medical License, #0101052145, 3/1/95 - 6/30/96 (inactive)

Washington Medical License, #MD00027469, 06/90 - 2/14/94 (inactive)

Federal DEA Registration Number, #BR5314543

State Controlled Substance Numbers: MD M40025, DC CS06-10806

National Provider Identifier 1669566691

Basic Life Support, American Heart Association (2003 – present)

## HONORS AND AWARDS

- 2016 PhRMA Research and Hope Award: Government Research in Autoimmune Disease
- 2016 Who's Who Top Doctor's Honors edition
- 2013 NIEHS Intramural Papers of the Month- September and November: Ultraviolet radiation exposure associated with clinical and autoantibody phenotypes in juvenile myositis; Genome-wide association study of dermatomyositis reveals genetic overlap with other autoimmune disorders
- 2011 Physician Researcher of the Year, US Public Health Service Physician's Professional Advisory Committee
- 2009- 2016 Best Doctors
- 2009 Selected for listing in *Women in Science at the National Institutes of Health*, Office of Research on Women's Health
- 2008, 2009, 2012 America's Top Pediatricians
- 2007 Hero Certificate, Cure JM Foundation ("For dedication to finding a cure for juvenile myositis")
- 2006 Elected member of the Henry Kunkel Society
- 2006 Certificate of Appreciation, US Public Health Service ("For exceptional performance in response to the USPHS Transformation objectives and mission by developing resources to mentor the professional development of Commissioned Corps physicians")
- 2006 Ann Hengel Lecturer in Pediatric Rheumatology. Medical College of Wisconsin, Milwaukee, Wisconsin. April 28, 2006.
- 2004 Commendation Medal, US Public Health Service ("For superior service in identifying the presence of microchimerism in juvenile-onset myositis")
- 2003 Schlager Family Visiting Professor Lectureship in Juvenile Dermatomyositis, Children's Hospital, Boston, MA, April 30, 2003
- 2000 Commendation Medal, US Public Health Service ("For exemplary performance of duty" in clinical review and policy development)
- 1999 Outstanding Unit Citation, US Public Health Service ("For innovative collaboration with academia, industry and the public in the development of programs for the treatment of rheumatoid arthritis")
- 1999 Unit Commendation, US Public Health Service ("For significant and exceptional performance in the review and licensing of new anti-TNF therapies for autoimmune

	disease”)
1998	Achievement Medal, US Public Health Service (“For validating the usefulness of clinical tools to assess disease activity in juvenile myositis with implications for many other pediatric and orphan diseases”)
1985-86	Eugene Stead Research Fellowship, Duke University School of Medicine
1985-86	Pharmaceutical Manufacturer's Medical Student Research Fellowship in Pharmacology-Clinical Pharmacology
1983	Phi Beta Kappa, Summa cum laude, Duke University

## **MENTORSHIP ACTIVITIES**

Directed research projects and mentored rheumatology fellows, medical students, PhD and master's thesis candidates, visiting scientists, undergraduate students, summer students at the National Institutes of Health and Food and Drug Administration (1996 – present)

### Recent trainees:

Takayuki Kishi MD PhD (6/15 – present): Assistant Professor, Pediatric Rheumatology, Tokyo Women's Hospital and Myositis Association research fellow; recipient of TMA Myositis Fellowship award

Hanna Kim MD MHSc (2015- present): NIAMS Schulman Scholar, Co-mentor with Raphaela Goldbach-Mansky: Biomarkers in JDM; recipient of CARRA- Cure JM grant award, American College of Rheumatology Distinguished Fellow

Payam Farhadi MD (2011- 6/15, 5/2016- present); Special volunteer and contractor, recipient 2015 DC Rheumatism Society Fellows Forum Poster award

### Selected Past Trainees:

Maya Chudamani (summer 2016): Montgomery Blair Math Science high school magnet student senior research project, Silver, Spring, MD (co-mentor with Raphaela Goldbach-Mansky); award recipient Washington Academy of Sciences

Nastaran Bayat MD (2011- 2016): Special volunteer, later contractor; Social and Scientific Systems, Inc., Bethesda, MD

Abdullah Faiq MPH (2011 – 2014): Special volunteer and contractor, Medical Student, Howard University, Washington DC

Saad Feroz BA (2012 –2013): Post-bac IRTA student; Medical Student, Eastern Virginia Medical School, Norfolk, VA

Adrienne Yip BA (2010 – 2012): Post-bac IRTA student; Recipient 2011 DC Rheumatism Society Fellows Forum Poster award, 2012 DC Rheum Society Fellows Forum award; Medical Student, University of Maryland School of Medicine, Baltimore, MD

Alexis Wilson (summer 2012, NIEHS Summer of Discovery student)

Anna Patnaik (summer 2011): Montgomery Blair Math Science high school magnet student- Biostatistics award at Blair magnet student research festival; College student, University of Maryland, College Park, MD

Sepehr Mesdaghinia MD (2010- 2011): Special volunteer; Rheumatology Fellow, Georgetown University Medical Center, Washington DC

Mona Shah- (2008 –2012): Special volunteer, PhD candidate student, George Washington University Department of Epidemiology; currently Program Officer, Robert Wood Johnson Foundation, Princeton, New Jersey

Lan Wu: (2007 – 2012): Part-time special volunteer, Undergraduate, Johns Hopkins University,

Baltimore, MD

Michael Harris-Love PT PhD (2005-2010): faculty member, DC VA Medical Center

Kathleen Coyle (2007 – 2008): NIAMS rheumatology fellow; Medical Officer, US Food and Drug Administration

Gulnara Mamyrova, MD PhD (2003 – 2008): Special volunteer and recipient of research fellowship grant awards from The Myositis Association and Cure JM; Research Fellow; recipient DC Rheumatism Society Fellows Research Award (2005-2007); currently Research Assistant Professor, Division of Rheumatology, George Washington University Department of Medicine

Jonathan Chipman (2007): NIEHS Summers of Discovery Student, PhD student in statistics, Boston University

Amy Li (2007 -08; 2009): Montgomery Blair Math Science high school magnet student- senior research project and Summers of Discovery Student, Duke University undergraduate student

Kim Nguyen (2008-09): Montgomery Blair Math Science high school magnet student- senior research project; Undergraduate, University of Maryland College Park

Jason Monroe (2005): NIEHS Summers of Discovery student, PhD student in Statistics, UCLA.

Leora Vegosen (2004-05): Masters of Environmental Science student, Johns Hopkins University School of Public Health; NIEHS 2004 Summers of Discovery student; Recipient of 2005-06 ACR Research and Education Foundation Medical/Graduate Student Achievement Award. Currently Editor for American Journal Experts, Department of Environmental Health Sciences, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

Catherine April Bingham MD (2004-06): Special volunteer, Pediatric rheumatology fellow, Columbia University, currently Assistant Professor, Pediatric Rheumatology, Hershey Medical Center

Lauren Komarow (2003): NIEHS Summers of Discovery student, MS in biostatistics, Univ. Michigan; Biostatistician, Center for Biostatistics in AIDS Research, Harvard School of Public Health

Adam Schiffenbauer (2002): NIEHS Summers of Discovery student, Staff Clinician, EAG, NIEHS, NIH

Tina Sanghvi (2002): NIEHS Summers of Discovery student and 2003 summer student, BA, Duke University; medical student, University of Iowa; ; currently Assistant Professor, Department of Radiology, University of Minnesota

Ben Laskin (1996), summer student- BA, Duke University, medical student University of Maryland, Baltimore; currently Attending Physician, Division of Nephrology, Children's Hospital of Philadelphia and Assistant Professor of Pediatrics, Perelman School of Medicine at the University of Pennsylvania

Ejaz Shamim, special volunteer, recipient American College of Rheumatology Medical Student Research Fellowship Award (1995); MD M.S., Director of Neurology, Kaiser Permanente Mid-Atlantic Permanente Medical Group, Rockville, MD

## **PROFESSIONAL ORGANIZATIONS**

Society for Clinical and Translational Science (2009- present)

Henry Kunkel Society (2006 – present)

Clinical Immunology Society (2006 – present)

U.S. Public Health Service Commissioned Officers Association (2003 – present)

Section on Environmental Health, American Academy of Pediatrics (2004 - present)

Childhood Arthritis and Rheumatology Research Alliance (CARRA) (2002 – present)

International Myositis Assessment and Clinical Studies (IMACS) Collaborative Study Group (2000 - present), Co-chair

Section on Uniformed Services, American Academy of Pediatrics (2000 – present)  
 Pediatric Rheumatology Collaborative Study Group (1998- present)  
 American Medical Association (1996 - present)  
 Pediatric Rheumatology Subsection, American College of Rheumatology (1994 - present)  
 Section on Pediatric Rheumatology, American Academy of Pediatrics (1994 - present)  
 Washington DC Rheumatism Society (1991 – 1994, 2003 - present)  
 Fellow, American College of Rheumatology (1990 - present)  
 Fellow, American Academy of Pediatrics, Pediatric Rheumatology Section (1990 - present)

## GRANT SUPPORT

2017 – 2021 Primary Associate Investigator, An Open-label Study of Sodium Thiosulfate for Treatment of Calcinosis Associated with Juvenile and Adult Dermatomyositis (\$1,559,120, CRADA with Hope Pharmaceuticals, EHS-CTCR-1) (10% effort)

2015 – 2017 Supervisor for Research Fellowship of Dr. Takayuki Kishi, The Myositis Association (\$100,000 salary support and benefits for 2 years) and Cure JM Foundation (\$26, 230); no funds being received by me or NIEHS

2015 – 2018 Co-supervisor for Schulman Scholar Post-Fellowship training for Dr. Hanna Kim with grant support from CARRA-Cure JM (\$125,000 award, no funds being received by me or NIEHS)

2016 Cure JM Foundation gift to NIEHS to support studies of juvenile myositis (\$8,000)

2013 - 2014 Cure JM Foundation gift to NIEHS to support studies of juvenile myositis (\$37,000)

2013 – 2014 Funding for ACR-EULAR Consensus Conference for the Development of Response Criteria for Adult and Juvenile Myositis (\$60,000 from NIH Office of Rare Diseases, NIEHS, NIAMS, Cure JM Foundation, UK Myositis Support Group and The Myositis Association)

2012 – 2016 Co-Principal Investigator, American College of Rheumatology-European League Against Rheumatism grant, “Development of Response Criteria for Adult and Juvenile Myositis” (\$130,000)

2011 – 2016 Co-Investigator, “Potential Environmental Triggers of Myositis”, The Myositis Association, from a cooperative agreement with the Department of Defense (W81XWH-11-1-0730) (\$596,575) (5% effort)

2009 – 2016 “The Myositis Genetics Consortium (MYOGEN)” Cure JM Foundation support - \$75K/yr. This project is identifying new genetic risk and protective factors for myositis via genome-wide association studies. (5% effort- no funds received by me or NIEHS)

2005 - 2009 American College of Rheumatology, Development of Outcome Measures for Myositis (\$15,000 to support database development and management)

2006 - 2009 Inter-agency agreement, NIAMS, Rituximab Therapy in Refractory Adult and Juvenile Idiopathic Inflammatory Myopathies (NIEHS as enrollment site, \$515,586)

2004 – 2007 Supervisor for Research Fellowship of Dr. Gulnara Mamyrova, Cure JM Foundation (salary support for 3 years; no funds received by me or NIEHS)

2002 – 2004 Supervisor for Research Fellowship of Dr. Gulnara Mamyrova, The Myositis Association (salary support for 2 years; no funds received by me or NIEHS)

2001, 2002 Co-Principal Investigator, NIH Office of Rare Diseases and NINDS funding for 2 workshops on

Outcome Assessment and Clinical Trial Design in the Idiopathic Inflammatory Myopathies (\$25,000 each year).

- 2001 – 2002 Co-Investigator, NIAMS R21 grant to Dr. Ann Reed, “Finalization of Outcomes and Design Issues for Myositis Trials” (\$83,000; no funds received by me or NIEHS)
- 1985-86 Pharmaceutical Manufacturer's Medical Student Research Fellowship in Pharmacology-Clinical Pharmacology

## **COMMITTEES AND SCIENTIFIC LEADERSHIP EXPERIENCE**

### **NIH, FDA and other Federal Agencies**

- Foundation of NIH Biomarkers Consortium- Inflammation and Immunity Steering Committee (2015– present)
- NIEHS Clinical Advisory Committee (ad hoc 2009- 2013; member 2014- present)
- NIEHS Inflammation Cross-Divisional Implementation Working Group (2012 – present)
- NIEHS Committee on Promotions IV (2011 – 2014)
- Member, National Institute of Environmental Health Sciences Institutional Review Board (June 2010 – present)
- U.S. Public Health Service Medical Review Board member (July 28, 2015, February 2014, December 2003, and June 2002)
- U.S. Public Health Service Promotion Board (date of service confidential)
- U.S. Public Health Service Physician’s Professional Advisory Committee Subcommittee on Mentoring (2004 - 2009)
- Alternate representative, NIH Clinical Center Medical Executive Committee (2008 – present)
- Resource Committee, NIH Clinical Center Barriers to Clinical Research Working Group (2008)
- Consultant, NIH Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease (2004 – 2007)
- NIEHS representative, NIH Clinical Research Center Pediatric Partners Care Team (2003 – present)
- NIEHS Code Red Team member for NIH Clinical Center; Designated evacuation safety leader for EAG, organizing annual safety and evacuation training (2003 – 2009)
- Children’s Longitudinal Environmental Health Study (National Children’s Study), Immunity, Infections and Vaccines Working Group (2002 – 2005)
- Data Safety Monitoring Board, Ingested Interferon Alpha: Prolongation of Permanence of the “Honeymoon” Phase in Newly Diagnosed Diabetes Mellitus (01-DK-0249) (2002 – 2006)
- NIEHS representative to NIH Pediatric Care Committee (2002 – present); Subcommittee on Normal Childhood Laboratory Values (2003- 2008); Subcommittee on Infection Control Policies at Children’s Inn (2004 – 2005)
- Member, Search Committee for NIEHS Staff Clinician (2001 – 2002; 2009-2010)
- Consulting reviewer, NIAMS/NIDDK/NIEHS Institutional Review Board (2001 - 2005)

### **Nationally and Internationally**

- Steering Committee and Vice Chair, Scientific Committee, 2<sup>nd</sup> Global Conference on Myositis in Washington DC (2016-2017)
- Chair, Steering Committee, Response Criteria Project for Adult and Juvenile Dermatomyositis and

Polymyositis (2012 – present)  
Medical Advisor to CSL Behring (2017 – present)  
Medical Advisor to Bristol Myers Squibb (2016 – present)  
Medical Advisor to aTyr, MedImmune, and Idera Pharmaceuticals (2014 – present)  
Scientific Committee, First International Conferences on Myositis, Stockholm Sweden (2015)  
Cure JM Foundation Medical Advisory Committee (2011 – present), Chair (4/16 – present)  
James T. Cassidy Award Selection Committee, American Academy of Pediatrics (2009 – 2012),  
Chair 2010-12  
Member and lead investigator of pediatric studies, International Myositis Genetics Consortium  
(MyoGen) (2006 – present)  
The Myositis Association: Medical Advisory Board Member (1996 - 2009); Vice Chair of Medical  
Advisory Board (2005–2007), Chair, Nominating Committee (2001–2006), Research  
Committee (2006 - 2008), Chair, Research Committee (2008-09); Registry Committee (2009  
– 10)  
Steering Committee, ACR-EULAR International Myositis Classification Criteria Project for the  
Idiopathic Inflammatory Myopathies (2004 – present)  
Steering Committee, Trial of Rituximab in Adult and Juvenile Idiopathic Inflammatory Myopathies  
(2002 – present); Publications Committee (2010- present)  
Childhood Arthritis and Rheumatology Research Alliance (CARRA), Member: Juvenile  
Dermatomyositis Scientific Group, Translational Research Working Group (2002 – present);  
Disease registry working group (2008-2014); Chair, Juvenile Dermatomyositis Data  
Repository Working Group (2009- 2014)  
Pediatric Rheumatology Study Section Chair, American College of Rheumatology (2006 – 2009)  
Editorial Board, Table of Biologic Therapies, Clinical Immunology Society (2008 – 2009)  
Communications Committee, Clinical Immunology Society (2006 – 2009)  
Executive Council, Pediatric Subsection, American College of Rheumatology (2003 – 2007);  
Vice Chair (2006 – 2008)  
Member and NIH Representative, Advisory Council, Pediatric Rheumatology Collaborative Study  
Group (2001 – present)  
Co-Chair and Co-Founder, International Myositis Assessment and Clinical Studies (IMACS)  
Collaborative Study Group (2000 - present); Chair, Meeting Committee, 2010 – present  
Abstract Selection Committee, Pediatric Rheumatology (1998), Myositis/Myopathies (2002, 2004,  
2010, 2012), American College of Rheumatology  
Advisor, the National Dermatomyositis Support Group, 1994-1996  
Advisory Committee, NIH/Hospital for Joint Diseases Registry for Neonatal Lupus (1994 - 2005)  
Juvenile Dermatomyositis American College of Rheumatology Working Group (founding chair)  
(1993 - 1999)

## **EDITORIAL AND REVIEW BOARD ACTIVITIES**

Editorial Boards: *Associate Editor, Annals of Pediatric Rheumatology*, 2011 – present

*Journal of Neuromuscular Diseases*, 2013 – present  
*International Journal of Rheumatology*, 2010 – present  
*World Journal of Rheumatology*, 2011 – 2015  
*The Open Arthritis Journal*, 2008 – 2012  
*The Open Rheumatology Journal*, 2007 –2012

Co-Editor, *Myositis and You: A Complete Family Guide to Juvenile Dermatomyositis and Other Inflammatory Myopathies*, The Myositis Association, Washington, 2007.

Grant reviews:

Dutch Arthritis Foundation, Reumafonds (2016)  
Arthritis Research UK (2013)  
EU-Rare JTC 2013 - European Research Projects on Rare Diseases European Union (2013)  
Action Medical Research and Medical Research Council, UK (2012)  
NIAMS Special Emphasis Panel – Clinical Trial Proposals (2011)  
American College of Rheumatology Research and Education Fund (2008)  
Prinses Beatrix Fonds (2008)  
The Myositis Association (2002 – 2008), Research Review Committee (2006- 2008);  
Chair, Research Review committee (2008-09)  
NIAMS RO1 applications (2004)  
NIAMS PO1 Program Project Grant Applications (2002)  
Univ Pittsburgh NIAMS Multipurpose Arthritis Center Development and Feasibility grants (2000)

Ad hoc journal reviewer: *Arthritis and Rheumatism, Arthritis Care and Research, Annals Rheumatic Diseases, PLoS One, Lancet, British Medical Journal, Arthritis Research and Therapy, Rheumatology, Clinical and Experimental Rheumatology, Journal of Rheumatology, Nature Reviews Rheumatology, Nature Reviews Neurology, Pediatrics, Muscle and Nerve, Journal of Neuroimmunology, Clinical and Experimental Rheumatology, Journal of Pediatric Rheumatology, Seminars in Arthritis and Rheumatism, Scandinavian Journal of Rheumatology, Journal of Pediatrics, Journal of Clinical Rheumatology, International Journal of Clinical Rheumatology, Archives of Dermatology, Pediatric Dermatology, British Journal of Dermatology, Expert Opinion on Drug Safety, Neuromuscular Disorders, Lupus, Clinical and Developmental Immunology, Journal of Molecular Diagnostics, Biomarkers in Medicine, Disease Biomarkers*

**SELECTED ORGANIZATION OF WORKSHOPS, SYMPOSIA, CONFERENCES**

Steering Committee and Vice Chair, Scientific Committee, Global Conference on Myositis in Potomac, MD, May 5-8, 2017 (planned)  
Co-organizer, The International Myositis Assessment and Clinical Studies (IMACS) Meeting, Washington DC, November 11, 2016  
Co-Chair, European Neuromuscular Centre (ENMC) International Workshop on Outcome Assessment for Dermatomyositis and Polymyositis, Heemskerk, Netherlands, September 18-20, 2015  
Co-organizer and co-moderator, The International Myositis Assessment and Clinical Studies (IMACS) Meeting, Boston, MA, November, 2014

Co-organizer and moderator, Response Criteria Project for Adult and Juvenile Dermatomyositis and Polymyositis, Paris, France, June 9-10, 2014

Co-organizer and co-moderator, The International Myositis Assessment and Clinical Studies (IMACS) Meeting, San Diego, CA, September 12, 2013

Co-organizer and co-moderator, The International Myositis Assessment and Clinical Studies (IMACS) Meeting, Washington, DC, November 12, 2012

Co-organizer, International Myositis Classification Criteria Project Meeting, November 9, 2012, Bethesda, MD

Session Chair, Environmental Issues, "Sex, Gender and Autoimmunity Through the Lifespan", American Autoimmune Related Diseases Association (AARDA), Chicago, IL, May 17, 2012

Co-organizer and co-moderator, The International Myositis Assessment and Clinical Studies (IMACS) Meeting, Atlanta, GA, November 7, 2010

Pediatric Rheumatology Study Section Chair, American College of Rheumatology (2006 – 2009): Organizer and moderator 3 study group meetings

Co-organizer and co-moderator, The International Myositis Assessment and Clinical Studies (IMACS) Meeting, Philadelphia, PA, October 17, 2009

Co-organizer and co-moderator, The International Myositis Assessment and Clinical Studies (IMACS) Meeting, San Francisco, CA, October 27, 2008

Co-organizer and co-moderator, The International Myositis Assessment and Clinical Studies (IMACS) Meeting, Boston, MA, November 10, 2007

Co-organizer and speaker, The International Myositis Assessment and Clinical Studies (IMACS) Meeting, Update on Myositis Clinical Studies, Washington, DC, November 14, 2006

Co-organizer and moderator, The International Myositis Assessment and Clinical Studies (IMACS) Meeting, Update on Myositis Clinical Studies and the IMACS Data Repository, San Diego, CA, November 13, 2005

Co-organizer and moderator, The ACR-EULAR International Myositis Classification Criteria Project Working Group Workshop, Dulles, VA, November 10-11, 2005

Co-organizer, 3rd International Myositis Assessment and Clinical Studies Workshop, Planning for Myositis Clinical Studies and the IMACS Data Repository, Orlando, FL, October 25-26, 2003

Co-organizer, 2nd International Myositis Assessment and Clinical Studies Workshop, Developing Consensus on Outcomes and Clinical Trial Design Issues in Adult and Juvenile Myositis, NIH Office of Rare Diseases, NIAMS, NINDS, NIEHS funded meeting, New Orleans, LA, October 22-23, 2002

Co-organizer and moderator, 1st International Myositis Assessment and Clinical Studies Workshop, Defining Improvement in Adult and Juvenile Myositis, NIH Office of Rare Diseases, NIAMS, NINDS, and NIEHS funded meeting, San Francisco, CA, November 9th-10th, 2001

Co-organizer and co-chair, FDA Juvenile Rheumatoid Arthritis Workshop, Bethesda, MD, July 23, 1996

## PUBLICATIONS

### Publications in Peer-Reviewed Journals

1. Abramson, S., H. Korchak, R. Ludewig, H. Edelson, K. Haines, R.I. Levin, **L. Rider**, and G. Weissmann. Modes of action of aspirin-like drugs. *Advances in Inflammation Research* 1985; 10: 31-35.
2. Abramson, S., H. Korchak, R. Ludewig, H. Edelson, K. Haines, R.I. Levin, R. Herman, **L. Rider**, S. Kimmel and G. Weissmann. Modes of action of aspirin-like drugs. *Proc. Natl. Acad. Sci.* 1985; 82: 7227-7231. PMID: 2997778. PMCID: PMC390822.

3. Weissmann G, Korchak H, Ludewig R, Edelson H, Haines K, Levin RI, Herman R, **Rider L**, Kimmel S, Abramson S. Non-steroidal anti-inflammatory drugs: how do they work? *Eur J Rheumatol Inflamm.* 1987;8(1):6-17. PMID: 3040419
4. **Rider, L.G.** and J.E. Niedel. Diacylglycerol accumulation and superoxide anion production in stimulated human neutrophils. *J. Biol. Chem.* 1987; 262:5603-5608. PMID: 3032939.
5. **Rider, L.G.**, R.W. Dougherty, and J.E. Niedel. Phorbol diesters and d-octanoylglycerol stimulate accumulation of both diacylglycerols and alkylacylglycerols in human neutrophils. *J. Immunol.* 1988; 140:200-207. PMID: 2826587.
6. **Rider, L.G.**, D.D. Sherry, and S.T. Glass. Neonatal lupus erythematosus simulating transient myasthenia gravis at presentation. *J. Pediatr.* 1991; 118:417-419. PMID: 1999784.
7. **Rider, L.G.**, W.R. Clarke, and J. Rutledge. Clinicopathologic conference: Pulmonary hypertension in a seventeen-year-old boy. *J. Pediatr.* 1992; 120:149-159. PMID: 1731014.
8. **Rider, L.G.**, Buyon, J.P., Rutledge, J., and D.D. Sherry. Treatment of neonatal lupus: Case report and review of the literature. *J. Rheumatol.* 1993; 20:1208-1211. PMID: 8371220.
9. **Rider, L.G.**, M.H. Wener, J. French, D.D. Sherry and P.M. Mendelman. Autoantibody production in Kawasaki syndrome. *Clin Exp Rheumatol.* 1993; 11:445-449. PMID: 8403592
10. **Rider, L.G.**, N. Raben, L. Miller, and C.L. Jelsema. The cDNAs for two forms of the *lyn* tyrosine kinase are expressed in rat mast cells and human myeloid cells. *Gene.* 1994; 138: 219-222. PMID: 8125304
11. **Rider, L.G.**, F.W. Miller, I.N. Targoff, D.D. Sherry, E. Samayoa, M. Lindahl, M.H. Wener, L.M. Pachman, and P.H. Plotz. Myositis-specific autoantibodies in children: A broadened spectrum of juvenile myositis. *Arthritis Rheumatism.* 1994; 37:1534-1538. PMID: 7945480.
12. **Rider, L.G.**, P. Thapa, M. DelBecarro, and P.M. Mendelman. Cerebrospinal fluid analysis in children with seizures. *Pediatr. Emerg. Care.* 1995; 11:226-229. PMID: 8532568.
13. **Rider, L.G.\***, N. Hirasawa\*, F. Santini, and M.A. Beaven. Activation of Mitogen-Activated Protein Kinase cascade is suppressed by low concentrations of dexamethasone in mast cells. *J. Immunol.* 1996; 157:2374-2380. \*These authors contributed equally. PMID: 8805635.
14. **Rider, L.G.**, B.M. Feldman, M.D. Perez, R.M. Rennebohm, C.B. Lindsley, L.S. Zemel, C.A. Wallace, S.H. Ballinger, S.L. Bowyer, A.M. Reed, M.H. Passo, I.M. Katona, F.W. Miller, and P.A. Lachenbruch, for the Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Development of Validated Disease Activity and Disease Damage Indices for the Juvenile Idiopathic Inflammatory Myopathies: I. Physician and Parent/Patient Global Assessments. *Arthritis Rheumatism.* 1997; 40: 1976-1983. PMID: 9365086.
15. **Rider, L.G.**, R.C. Gurley, J.P. Pandey, I. Garcia-de la Torre, A.E. Kalovidouris, T.P. O'Hanlon, L.A. Love, R.C.M. Hennekam, L.L. Baumbach, H.E. Neville, C.A. Garcia, J. Klingman, M. Gibbs, M.H. Weisman, I.N. Targoff, F.W. Miller. Clinical, serologic, and immunogenetic features of familial idiopathic inflammatory myopathy. *Arthritis Rheumatism.* 1998; 41:710-719. PMID: 9550481.
16. Buyon, J.P., R. Hiebert, J. Copel, J. Craft, D. Friedman, M. Katholi, L.A. Lee, T.T. Provost, M. Reichlin, **L. Rider**, A. Rupel, S. Saleeb, W.L. Weston, M.L. Skovron. Autoimmune-associated congenital heart block: Demographics, mortality, morbidity and recurrence rates obtained from a national neonatal lupus

- registry. *J. Amer. College Cardiology*. 1998; 31:1658-1666. PMID: 9626848.
17. Summers, R.M., A.M. Brune, P.L. Choyke, C.K. Chow, N.J. Patronas, F.W. Miller, P.H. White, J.D. Malley, **L.G. Rider**. Juvenile idiopathic inflammatory myopathy: Exercise-induced changes in muscle at short inversion time inversion-recovery MR imaging. *Radiology*. 1998; 209:191-196. PMID: 9769831
  18. **Rider, L.G.**, E. Shamim, S. Okada, J.P. Pandey, I.N. Targoff, T.P. O'Hanlon, H.A. Kim, Y.S. Lim, H. Han, Y.W. Song, F.W. Miller. Genetic risk and protective factors for idiopathic inflammatory myopathy in Koreans and American Whites: A tale of two loci. *Arthritis Rheumatism*. 1999; 42:1285-1290. PMID: 10366124.
  19. Lovell D.J., CB. Lindsley, RM. Rennebohm, SH. Ballinger, SL. Bowyer, EH Giannini, JE Hicks, JE Levinson, R. Mier, LM Pachman, MH Passo, MD Perez, AM Reed, KN Schickler, M. Smith, LS Zemel, **LG Rider**, in cooperation with the Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Development of validated disease activity and disease damage indices for the juvenile idiopathic inflammatory myopathies: II. The Childhood Myositis Assessment Scale: A quantitative tool for the evaluation of muscle function. *Arthritis Rheumatism*. 1999; 42:2213-2219. PMID: 10524696.
  20. Laskin, B.L, Choyke P, Keenan G, Miller F.W., **Rider L.G.** Novel gastrointestinal tract abnormalities in juvenile dermatomyositis. *J Pediatrics*. 1999; 135:371-374. PMID: 10484806.
  21. **Rider, L.G.\***, C. Artlett\*, C.B. Foster, A. Ahmed, T. Neeman, S. J. Channock, S. Jimenez, F.W. Miller, for the Childhood Myositis Heterogeneity Study Group. Polymorphisms in the IL-1 receptor antagonist gene VNTR are possible risk factors for juvenile idiopathic inflammatory myopathies. *Clin Exper. Immunol*. 2000; 121:47-52. \*These authors contributed equally. PMID: 10886238. PMCID: PMC1905682
  22. Kimball, A.B., R.M. Summers, M. Turner, E. Dugan, J. Hicks, F.W. Miller, and **L.G. Rider**. Magnetic resonance imaging detects occult skin and subcutaneous abnormalities in juvenile dermatomyositis: Implications for diagnosis and therapy. *Arthritis Rheumatism*. 2000; 43:1866-1873. PMID: 10943878.
  23. Wise RP, ME Salive, MM Braun, G Terracciano Mootrey, JF Seward, **L.G. Rider**, PR Krause. Post-licensure safety surveillance for varicella vaccine. *JAMA*. 2000; 284:1271-1279. PMID: 10979114.
  24. Artlett C.M., R. Ramos, S.A. Jimenez, K. Patterson, F.W. Miller, and **L.G. Rider**, for the Childhood Myositis Heterogeneity Collaborative Study Group. Chimeric cells of maternal origin in juvenile idiopathic inflammatory myopathies. *Lancet*. 2000; 356:2155-2156. PMID: 11191545.
  25. Huber A, J.E. Hicks, P.A. Lachenbruch, M.D. Perez, L.S. Zemel, R.M. Rennebohm, C.A. Wallace, C.B. Lindsley, M.H. Passo, S.H. Ballinger, S.L. Bowyer, A.M., P.H. White, I.M. Katona, F.W. Miller, **L.G. Rider\***, and B.M. Feldman\*. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. III. The Childhood Health Assessment Questionnaire (CHAQ). *J Rheumatology*. 2001; 28:1106-1111. \*These authors contributed equally. PMID: 11361197.
  26. Artlett CM, FW Miller, **LG Rider**, for the Childhood Myositis Heterogeneity Collaborative Study Group. Persistent maternally derived peripheral microchimerism is associated with the juvenile idiopathic inflammatory myopathies. *Rheumatology*. 2001; 40:1279-1284. PMID: 11709612.
  27. Mitchell JP, Dennis GJ, Rider LG. Juvenile dermatomyositis presenting with anasarca: a positive indicator of severe disease activity. *J Pediatr* 2001; 138: 942-5. PMID: 11391348.

28. Hicks JE, B. Drinkard, R. Summers, and **L.G. Rider**. Decreased aerobic exercise capacity in children with juvenile dermatomyositis. *Arthritis Rheum (Arthritis Care Research)* 2002; 47: 118-123. PMID: 11954004.
29. Shamim EA, **LG Rider**, JP Pandey, TP O'Hanlon, LJ Jara, E Samayoa, R Burgos-Vargas, J Vazquez-Mellado, J Alcocer-Varela, M Salazar-Paramo, AG Garcia Kutzbach, JD Malley, IN Targoff, I Garcia de la Torre, and FW Miller. Idiopathic inflammatory myopathy phenotypes and genotypes differ in Mesoamerican Mestizos and North American Caucasians suggesting ethnogeographic influences in the genetics and clinical expression of myositis. *Arthritis Rheum.* 2002; 46: 1885 - 1893. PMID: 12124873.
30. **Rider LG\***, AS Schiffenbauer\*, M Zito, KL Lim, A Ahmed, LS Zemel, RM Rennebohm, MH Passo, RM Summers, JE Hicks, PA Lachenbruch, MP Heyes, FW Miller, in cooperation with the Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Neopterin and quinolinic acid are surrogate measures of disease activity in the juvenile idiopathic inflammatory myopathies. *Clin. Chem.* 2002; 48: 1681–1688. \*These authors contributed equally. PMID: 12324484.
31. Artlett CM, O'Hanlon TP, Lopez AM, Song YW, Miller FW, and **Rider LG** for the Childhood Myositis Heterogeneity Collaborative Study Group. HLA-DQA1 is not an apparent risk factor for microchimerism in patients with various autoimmune diseases and in healthy individuals.. *Arthritis Rheum.* 2003; 48: 2567-2572. PMID: 13130476.
32. Drinkard BE, Hicks J, Danoff J, **Rider LG**. Fitness as a determination of the oxygen uptake/work rate slope in healthy children and children with inflammatory myopathy. 2003; *Can J Appl. Physiol.* 28: 888 - 897. PMID: 14992126.
33. Okada, S, Weatherhead, E, Targoff, IN, Wesley, R, Miller, FW; **International Myositis Collaborative Study Group**. Global surface ultraviolet radiation intensity may modulate the clinical immunologic expression of autoimmune muscle disease. *Arthritis Rheum.* 2003; 48:2285-2293. PMID: 12905483.
34. **Rider, LG**, Giannini, E.H, Harris-Love, M, Joe, G, Isenberg, D, Pilkington, C, Lachenbruch, P.A, Miller, F.W. Defining Clinical Improvement in Adult and Juvenile Myositis. *J Rheumatol.* 2003;30(3):603-617. PMID: 12610824.
35. Ruperto, N, Ravelli, A, Murray, K.J, Lovell, D.J, Andersson-Gare, B, Feldman, B.M, Garay, S, Kuis, W, Machado, C, Pachman, L, Prieur, A.M, **Rider L.G.**, Silverman, E, Tsitsami, E, Woo, P, Giannini, E.H, Martini, A. Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. *Rheumatology.* (Oxford) 2003;42(12):1452-1459. PMID: 12832713.
36. Isenberg DA, Allen E, Farewell V, Ehrenstein M Hanna M G, Lundberg I E, Oddis C, Pilkington C, Plotz P, Scott D, Venkovsky J, **Rider L**, Miller F., for the International Myositis and Clinical Studies Group (IMACS). International consensus outcome measures for patients with idiopathic inflammatory myopathies: Development and initial validation of myositis activity and damage indices in patients with adult onset disease. *Rheumatology*, 2004; 43: 49-54. PMID: 12867580.
37. Rennebohm RM, Jones K, Huber AM, Ballinger SH, Feldman BM, Hicks J, Katona IM, Lindsley CB, Miller FW, Passo MH, Perez MD, Reed AM, Wallace CA, White PH, Zemel LS, Lachenbruch PA, Hayes JR, and **Rider LG**, for the Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Normal scores for nine maneuvers of the Childhood Myositis Assessment Scale (CMAS). *Arthritis Rheum (Arthritis Care Res)*; 2004; 51: 365-370. PMID: 15188320.

38. Huber AM, Feldman BM, Rennebohm RM, Hicks JE, Lindsley CB, Perez MD, Zemel LS, Wallace CA, Ballinger SH, Passo MH, Reed AM, Summers RM, White PH, Katona IM, Miller FW, Lachenbruch PA, and **Rider LG**, for the Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Validation and clinical significance of the Childhood Myositis Assessment Scale (CMAS) for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. *Arthritis Rheum*; 2004; 50: 1595-1603. PMID: 15146430.
39. Lohmann Siegel K, Hicks JE, Koziol DE, Gerber LH, **Rider LG**. Walking ability and its relationship to lower extremity muscle strength in children with idiopathic inflammatory myopathies. *Arch Phys Med Rehab*; 2004;85: 767-71. PMID: 15129401.
40. **Rider LG**, Giannini EH, Brunner HI, Ruperto N, James-Newton L, Reed AM, Lachenbruch PA, Miller FW, for the International Myositis Assessment and Clinical Studies Group. International consensus outcome measures for patients with idiopathic inflammatory myopathies: Preliminary Definitions of Improvement for Adult and Juvenile Myositis. *Arthritis Rheum*; 2004;50(7): 2281-2290. PMID: 15248228.
41. Chung YL, **Rider LG**, Bell JD, Summers RM, Zemel LS, Rennebohm RM, Passo MH, Hicks J, Miller FW, and Scott DL, for the Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Muscle metabolites, detected in urine by proton spectroscopy, correlate with disease damage in juvenile idiopathic inflammatory myopathies. *Arthritis and Rheumatism (Arthritis Care and Research)*. 2005; 53: 565-570. PMID: 16082628.
42. Oddis CV\*, **Rider LG\***, Reed AM, Ruperto N, Brunner HI, Koneru B, Feldman BM, Giannini EH, Miller FW, for the International Myositis Assessment and Clinical Studies Group (IMACS). International Consensus Guidelines for Trials of Therapies in the Idiopathic Inflammatory Myopathies. *Arthritis and Rheumatism*. 2005; 52: 2607 – 2715. \*These authors contributed equally. PMID: 16142757.
43. Mamyrova G, **Rider LG**, Haagensohn L, Wong S, Brown KE. Parvovirus B19 and onset of juvenile dermatomyositis. *JAMA*; 2005. 294: 2170-2171. PMID: 16264157.
44. O'Hanlon TP, Mercatante Carrick D, Arnett FC, Reveille JD, Carrington M, Gao X, Oddis CV, Morel PA, Malley JD, Malley K, Dreyfuss J, Shamim EA, **Rider LG**, Chanock SJ, Foster CB, Bunch T, Plotz PH, Love LA and Miller FW. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: Distinct HLA-A, -B, -Cw, -DRB1 and -DQA1 allelic profiles and motifs define clinicopathologic groups in Caucasians. *Medicine*. 2005; 84: 338–349. PMID: 16267409.
45. Nagaraju, K, **Rider LG**, Fan C, Cutting S, Thapliyal R, Mitsak M, Rawat R, Raben N, Patterson K, Grundtman C, Miller FW, Plotz PH, Hoffman E, and Lundberg IE. Endothelial cell activation and neovascularization are prominent in dermatomyositis. 2006. *Journal of Autoimmune Diseases*. 2006; 3:2 PMID: 16504012. PMCID: PMC1397829.
46. O'Hanlon TP, Mercatante Carrick D, Targoff IN, Arnett FC, Reveille JD, Carrington M, Gao X, Oddis CV, Morel PA, Malley JD, Malley K, Shamim EA, **Rider LG**, Chanock SJ, Foster CB, Bunch T, Blackshear PJ, Plotz PH, Love LA, and Miller FW. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1, and -DQA1 allelic profiles distinguish European American patients with different myositis autoantibodies. *Medicine*. 2006; 85: 111-127. PMID: 16609350.
47. Pavletic S, Martin P, Lee SJ, Mitchell S, Jacobsohn D, Cowen EW, Turner ML, Akpek G, Gilman A, McDonald G, Schubert M, Berger A, Bross P, Chien JW, Couriel D, Dunn JP, Fall-Dickson J, Farrell A, Flowers ME, Greinix H, Hirschfeld S, Gerber L, Kim S, Knobler R, Lachenbruch PA, Miller FW,

- Mittleman B, Papadopoulos E, Parsons SK, Przepiorka D, Robinson M, Ward M, Reeve B, **Rider LG**, Shulman H, Schultz KR, Weisdorf D, Vogelsang G, Response Criteria Working Group. Measuring Therapeutic Response in Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease: IV. Response Criteria Working Group Report. *Biology of Blood and Marrow Transplantation*. 2006; 12: 252-266. PMID: 16503494.
48. Jain M, Smith M, Cintas H, Koziol D, Wesley R, Harris-Love M, Lovell D, **Rider LG**, Hicks, J. Intra-rater and inter-rater reliability of the 10-point manual muscle test of strength in children with juvenile idiopathic inflammatory myopathies. *Physical and Occupational Therapy in Pediatrics*. 2006; 26: 5 – 18. PMID: 16966313.
49. Targoff IN, Mamyrova G, Trieu EP, Perurena O, Koneru B, O'Hanlon TP, Miller FW\*, **Rider LG\***, for the Childhood Myositis Heterogeneity and International Myositis Collaborative Study Groups. A Novel Autoantibody to a 155 kd Protein is Associated with Dermatomyositis. *Arthritis and Rheumatism*. 2006; 54: 3682- 3689. \*These authors contributed equally. PMID: 17075819.
50. O'Hanlon TP, **Rider LG**, Mamyrova G, Targoff IN, Arnett FC, Reveille JD, Carrington M, Gao X, Oddis CV, Morel PA, Malley JD, Malley K, Shamim EA, Chanock SJ, Foster CB, Bunch T, Reed AM, Love LA, Miller FW. HLA polymorphisms in African Americans with idiopathic inflammatory myopathies: Allelic profiles distinguish patients with different clinical phenotypes and myositis autoantibodies. *Arthritis and Rheumatism*. 2006; 54: 3670 - 3681. PMID: 17075818.
51. Mamyrova,G, O'Hanlon TP, Monroe JB, Mercatante Carrick D, Malley JD, Adams S, Reed AM, Shamim EA, James-Newton L, Miller FW, **Rider LG**, for the Childhood Myositis Heterogeneity Collaborative Study Group. Immunogenetic risk and protective factors for juvenile dermatomyositis in Caucasians. *Arthritis and Rheumatism*. 2006; 54: 3979–3987. PMID: 17133612. PMCID: PMC2063456.
52. Mamyrova G, Kleiner DE, James-Newton L, Shaham B, Miller FW, **Rider LG**. Late-Onset Gastrointestinal Pain in Juvenile Dermatomyositis as a Manifestation of Ischemic Ulceration from Chronic Endarteropathy. *Arthritis and Rheumatism (Arthritis Care and Research)*. 2007; 57: 881 - 884. PMID: 17530691. PMCID: PMC2099313.
53. Vegosen LJ, Weinberg CR, O'Hanlon TP, Targoff IN, Miller FW, **Rider LG**. Seasonal Patterns in Myositis Subgroups Suggest an Etiologic Role of Early Environmental Exposures. *Arthritis and Rheumatism*. 2007; 56: 2719 - 2728. PMID: 17665425. PMCID: PMC2151046.
54. Huber AM, Dugan EM, Lachenbruch PA, Feldman BM, Perez MD, Zemel LS, Lindsley CB, Rennebohm RM, Wallace CA, Wallace CA, Passo MH, Reed AM, Bowyer SL, Ballinger SH, Miller FW, **Rider LG**. The Cutaneous Assessment Tool (CAT): Development and reliability in juvenile idiopathic inflammatory myopathy. *Rheumatology*. 2007; 46 (10): 1606-1611. PMID: 17890275. PMCID: PMC2598780.
55. Huber AH, Dugan EM, Lachenbruch PA, Feldman BM, Perez MD, Zemel LS, Lindsley CB, Rennebohm RM, Wallace CA, Passo MH, Reed AM, Bowyer SL, Ballinger SH, Miller FW, **Rider LG**, in cooperation with the Juvenile Dermatomyositis Disease Activity Collaborative Study Group Preliminary validation and clinical meaning of the Cutaneous Assessment Tool (CAT) in juvenile dermatomyositis. *Arthritis and Rheumatism (Arthritis Care and Research)*. 2008;59: 214–221. PMID: 18240194.
56. Huber AH, Lachenbruch PA, Dugan EM, Miller FW, **Rider LG**, for the Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Alternative Scoring of the Cutaneous Assessment Tool

(CAT) in Juvenile Dermatomyositis: Results Using Abbreviated Formats. *Arthritis and Rheumatism (Arthritis Care and Research)*. 2008; 59: 352-356. PMID: 18311761. PMCID: PMC2598766.

57. Bingham A, Mamyrova G, Rother KI, Oral E, Cochran E, Premkumar A, Kleiner D, James-Newton L, Targoff IN, Pandey JP, Mercatante Carrick D, Sebring N, O'Hanlon TP, Ruiz Hidalgo M, Turner M, Gordon LB, Laborda J, Bauer SR, Blackshear PJ, Imundo L, Miller FW, **Rider LG**, for the Childhood Myositis Heterogeneity Study Group. Predictors of Acquired Lipodystrophy in Juvenile-Onset Dermatomyositis and a Gradient of Severity. *Medicine*.2008; 87: 70- 86. PMID: 18344805. PMCID: PMC2674585.
58. O'Hanlon TP, **Rider LG**, Schiffenbauer A, Targoff IN, Malley JK, Pandey JP, Miller FW. Immunoglobulin Gene Polymorphisms are Susceptibility Factors in Clinical and Autoantibody Subgroups of the Idiopathic Inflammatory Myopathies. 2008. *Arthritis and Rheumatism*. 58: 3239 – 3246. PMID: 18821675. PMCID: PMC2682358.
59. Mamyrova G., O'Hanlon TP, Sillers L, Malley K, James-Newton L, Parks CG, Cooper GS, Pandey JP, Miller FW, **Rider LG**, for the Childhood Myositis Heterogeneity Collaborative Study Group. Cytokine Gene Polymorphisms as Risk and Severity Factors for Juvenile Dermatomyositis. *Arthritis and Rheumatism*. 2008;58(12):3941-3950. PMID: 19035492. PMCID: PMC2674642.
60. Harris-Love MO, Shrader JA, Koziol D, Pahlajani N, Jain M, Smith M, Cintas HL, McGarvey CL, James-Newton L, Pokrovnichka A, Moini R, Cabalar I, Lovell DJ, Wesley R, Plotz PH, Miller FW, Hicks JE, **Rider LG**. Distribution and Severity of Weakness Among Patients with Polymyositis, Dermatomyositis and Juvenile Dermatomyositis. *Rheumatology*. 2009; 48: 134 - 139. PMID: 19074186. PMCID: PMC2634286.
61. Lachenbruch PA, Miller FW, **Rider LG**. On Determining the Effects of Therapy on Disease Damage in Non-Randomized Studies with Multiple Treatments: A study of Juvenile Myositis." *Comm. In Statist. - Theory and Methods*. 2009, 38: 3268-3281. PMID: 20209035. PMCID: PMC2832328.
62. Coyle K, Rother KI, Weise M, Ahmed A, Miller FW, **Rider LG**. Metabolic abnormalities and cardiovascular risk factors in children with myositis. *Journal of Pediatrics*. 2009. 155(6):882-7. PMID: 19643439. PMCID: PMC2809424.
63. **Rider LG**, Lachenbruch PA, Monroe JB, Ravelli A, Cabalar I, Feldman BM, Villalba ML, Myones BL, Pachman LM, Rennebohm RM, Reed AM, Miller FW, for the International Myositis Assessment and Clinical Studies Group (IMACS). Damage Extent and Predictors in Adult and Juvenile Dermatomyositis and Polymyositis Using the Myositis Damage Index. *Arthritis and Rheumatism*, 2009;60(11):3425-3435. PMID: 19877055. PMCID: PMC2793533.
64. Eidelman N, Boyde A, Bushby AJ, Howell PG, Sun J, Miller FW, Robey PG, **Rider LG**. Microstructure and mineral composition of dystrophic calcification associated with the inflammatory myopathies. *Arthritis Research and Therapy*, 2009 Oct 26;11(5): R159. PMID: 19857267. PMCID: PMC2787294.
65. Javierre BM, Fernandez AF, Richter J, Al-Shahrour F, Martin-Subero JI, Rodriguez-Ubrea J, Berdasco M, Fraga MF, O'Hanlon TP, **Rider LG**, Jacinto FV, Lopez-Longo FJ, Dopazo J, Forn M, Peinado MA, Carreño L, Sawalha AH, Harley JB, Siebert R, Esteller M, Miller FW and Ballestar E. Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus. *Genome Research*. 2010 20: 170-179. PMID: 20028698. PMCID: PMC2813473.
66. Huber AM, Giannini E, Bowyer SL, Kim S, Lang B, Lindsley CB, Pachman LM, Pilkington C, Reed AM, Rennebohm RM, **Rider LG**, Wallace CA, Feldman BM. Protocols for the Initial Treatment of Moderately

Severe Juvenile Dermatomyositis: Results of a Children's Arthritis and Rheumatology Research Alliance Consensus Conference. *Arthritis Care and Research*. 2010; 62: 219-225. PMID: 20191521. PMCID: PMC2909837.

67. **Rider LG**, Koziol D, Giannini EH, Jain MS, Smith MR, Whitney-Mahoney K, Feldman BM, Wright SJ, Lindsley CB, Pachman LM, Villalba ML, Lovell DJ, Bowyer SL, Plotz PH, Miller FW, Hicks JE. Validation of Manual Muscle Testing and a Subset of Eight Muscles (MMT8) in Adult and Juvenile Idiopathic Inflammatory Myopathies. *Arthritis Care and Research*. 2010; 62(4): 465-472. PMID: 20391500. PMCID: PMC2924143.
68. **Rider LG**, Wu L, Mamyrova G, Targoff IN, Miller FW, for the Childhood Myositis Heterogeneity Collaborative Study Group. Environmental Factors Preceding Illness Onset Differ in Phenotypes of the Juvenile Idiopathic Inflammatory Myopathies. *Rheumatology*. 2010; 49(12):2381-90. PMID: 20802007. PMCID: PMC2981509.
69. Ruperto N, Pistorio A, Ravelli A, **Rider LG**, Pilkington C, Oliveira S, Wulfraat N, Espada G, Garay S, Cuttica R, Hofer M, Quartier P, Melo-Gomes J, Reed AM, Wierzbowska M, Feldman BM, Harjacek M, Huppertz HI, Nielsen S, Flato B, Lahdenne P, Michels H, Murray KJ, Punaro L, Rennebohm R, Russo R, Balogh Z, Rooney M, Pachman LM, Wallace C, Hashkes P, Lovell DJ, Giannini EH, Martini A, for the Pædiatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG). The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis. *Arthritis Care and Research*, 2010;62(11):1533-41. PMID: 20583105. PMCID: PMC2964396.
70. O'Hanlon TP, **Rider LG**, Gan L, Fannin R, Paules RS, Umbach DM, Weinberg C, Shah RR, Mav D, Gourley M, Miller FW. Gene expression profiles from discordant monozygotic twins suggest that molecular pathways are shared among multiple systemic autoimmune diseases. *Arthritis Res Ther*. 2011 Apr 26;13(2): R69. PMID: 21521520. PMCID: PMC3132064.
71. Katz JD, Mamyrova G, Agarwal S, Jones OY, Bollar H, Huber AM, **Rider LG**, White PH. Parents' perception of self-advocacy of children with myositis: an anonymous online survey. *Pediatric Rheumatology*. 2011, 9:10. PMID: 21649897. PMCID: PMC3118375
72. O'Hanlon TP, Li Z, Gan L, Gourley MF, **Rider LG** and Miller FW. Plasma Proteomic Profiles from Disease-Discordant Monozygotic Twins Suggest that Molecular Pathways are Shared in Multiple Systemic Autoimmune Diseases. *Arthritis Research & Therapy*. 2011;13(6): R181. PMID: 22044644. PMCID: PMC3315681.
73. Wallace CA, Giannini EH, Huang B, Itert L, Ruperto N; **Childhood Arthritis Rheumatology Research Alliance; Pediatric Rheumatology Collaborative Study Group**; Paediatric Rheumatology International Trials Organisation. American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. *Arthritis Care Res (Hoboken)*. 2011 Jul;63(7):929-36. PMID: 21717596.
74. Arabshahi B, Silverman RA, Jones, OY, **Rider LG**. Abatacept and Sodium Thiosulfate for Treatment of Recalcitrant Juvenile Dermatomyositis Complicated by Ulceration and Calcinosis. *J Pediatrics*. 2012; 160(3):520-2. PMID: 22244459. PMCID: PMC3306811.
75. Forsberg LA, Rasi C, Razzaghian HR, Pakalapati G, Waite L, Thilbeault KS, Ronowicz A, Wineinger NE, Tiwari HK, Boomsma D, Westerman MP, Harris JR, Lyle R, Essand M, Eriksson F, Assimes TL, Iribarren C, Strachan E, O'Hanlon TP, **Rider LG**, Miller FW, Giedraitis V, Lannfelt L, Ingelsson M, Piotrowski A, Pedersen NL, Absher D, Dumanski JP. Age-Related Somatic Structural Changes in the

Nuclear Genome of Human Blood Cells. *Am J Hum Genet.* 2012, 10;90(2):217-28. PMID: 22305530. PMCID: PMC3276669.

76. Parks CG, D'Aloisio AA, DeRoo LA, Huiber K, **Rider LG**, Miller FW, Sandler DP. Childhood socioeconomic factors and perinatal characteristics influence development of rheumatoid arthritis (RA) in adulthood. *Ann Rheum Dis.* 2013 Mar;72(3):350-6. PMID: 22586176. PMCID: PMC5029277
77. Lazarevic D, Pistorio A, Palmisani E, Miettunen P, Ravelli A, Pilkington C, Wulfraat N, Malattia C, Garay S, Hofer M, Quartier P, Dolezalova P, Calvo I, Ferriani V, Ganser G, Kasapcopur O, Melo-Gomes JA, Reed AM, Wierzbowska M, **Rider LG**, Martini A, Ruperto N for the Paediatric Rheumatology International Trials Organisation (PRINTO). The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis. *Ann Rheum. Dis.* 2013 May;72(5):686-93. PMID: 22736096 PMCID: PMC2964396.
78. Volochayev R, Csako G, Wesley R, **Rider LG** and Miller FW. Laboratory Test Abnormalities are Common in Polymyositis and Dermatomyositis and Differ among Clinical and Demographic Groups. *The Open Rheumatology Journal*, 2012, 6, 54-63. PMID: 22723809. PMCID: PMC3377888.
79. Oddis CV, Reed AM, Aggarwal R, **Rider LG**, Ascherman DP, Levesque MC, Barohn RJ, Feldman BM, Koontz DC, Fertig N, Kelley SS, Pryber SL, Miller FW and Rockette HE and the Rituximab in Myositis (RIM) Study Group. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. *Arthritis and Rheumatism.* 2013 Feb;65(2):314-24. PMID: 23124935. PMCID: PMC3558563.
80. Shah M, Mamyrova G, Targoff IN, Huber AM, Malley JD, Rice MM, Miller FW, **Rider LG**, with the Childhood Myositis Heterogeneity Collaborative Study Group. The Clinical Phenotypes of the Juvenile Idiopathic Inflammatory Myopathies. *Medicine (Baltimore).* 2013 Jan;92(1):25-41. PMID: 23263716. PMCID: PMC4580479
81. **Rider LG**, Shah M, Mamyrova G\*, Huber AM\*, Rice MM, Targoff IN, Miller FW, with the Childhood Myositis Heterogeneity Collaborative Study Group. The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. *Medicine (Baltimore).* 2013. 92(4): 223-243. \*, \*\* These authors contributed equally to this work. PMID: 23877355. PMCID: PMC3721421.
82. Shah M, Targoff IN, Rice MM, Miller FW, **Rider LG**, with the Childhood Myositis Heterogeneity Collaborative Study Group. Brief Report: Ultraviolet Radiation Exposure is Associated with Clinical and Autoantibody Phenotypes in Juvenile Myositis. *Arthritis and Rheumatism*, 2013; 65(7):1934-41. PMID: 23658122. PMCID: PMC3727975.
83. Razzaghian HR, Forsberg LA, Prakash KR, Przerada S, Paprocka H, Zywicka A, Westerman MP, Pedersen NL, O'Hanlon TP, **Rider LG**, Miller FW, Srulek E, Jankowski M, Zegarski W, Piotrowski A, Absher D, Dumanski JP. Post-zygotic and inter-individual structural genetic variation in a presumptive enhancer element of the locus between the *IL10R $\beta$*  and *IFNAR1* genes. *PLoS ONE* 2013;8(9): e67752...PMID: 24023707, PMCID: PMC3762855.
84. Mamyrova G, Katz JD, Jones RV, Targoff IN, Lachenbruch PA, Jones OY, Miller FW, **Rider LG**, with the Childhood Myositis Heterogeneity Collaborative Study Group. Clinical and Laboratory Features Distinguishing Juvenile Polymyositis and Muscular Dystrophy in Children. *Arthritis Care and Research*, 2013;65(12):1969-75.2013. PMID: 23925923. PMCID: PMC5083635
85. Miller FW\*, Cooper RG\*, Vencovsky J, **Rider LG**, Danko K, Wedderburn LR, Lundberg IE, Pachman LM, Reed AM, Ytterberg SR, Padyukov L, Selva-O'Callaghan A, Radstake T, Isenberg DA, Chinoy H,

Ollier WER, O'Hanlon TP, Peng B, Lee A, Lamb JA, Chen W, Amos CI\*\*, Gregersen PK\*\*, with the Myositis Genetics Consortium. Genome-wide Association Study of Dermatomyositis Reveals Genetic Overlap with other Autoimmune Disorders. *Arthritis and Rheumatism*. 2013;65(12):3239-47. \*, \*\* These authors contributed equally to this work. PMID:23983088. PMCID: PMC3934004

86. Huber AM, Mamyrova G, Lachenbruch PA, Lee JA, Katz JD, Targoff IN, Miller FW, **Rider LG**, with the Childhood Myositis Heterogeneity Study Group. Early Illness Features Associated with Mortality in the Juvenile Idiopathic Inflammatory Myopathies. *Arthritis Care and Research*, 2014;66(5):732-40. PMID: 24151254. PMCID: PMC4646219
87. Aggarwal R, Bandos A, Reed AM, Ascherman DP, Barohn RJ, Feldman BM, Miller FW, **Rider LG**, Harris-Love MO, Levesque MC, Oddis CV and the RIM Study Group. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. *Arthritis and Rheumatology*, 2014;66(3):740-9. PMID: 24249095 PMCID: PMC3987896.
88. Gan L, O'Hanlon TP, Gordon A, **Rider LG**, Miller FW and Burbelo PD. Twins Discordant for Myositis and Systemic Lupus Erythematosus Show Markedly Enriched Autoantibodies in the Affected Twin Supporting Environmental Influences in Pathogenesis. *BMC Musculoskelet Disord*. 2014;15(1):67. PMID: 24602337 PMCID: PMC3973849
89. **Rider LG**, Yip AL, Horkayne-Szakaly I, Volochayev R, Shrader JA, Turner ML, Kong HH, Jain MS, Jansen AV, Oddis CV, Fleisher TA, Miller FW. Novel assessment tools to evaluate clinical and laboratory responses in a subset of patients enrolled in the Rituximab in Myositis trial. *Clinical and Experimental Rheumatology*, 2014;32(5):689-96. PMID: 25068290 PMCID: PMC4644185
90. Wing S, **Rider LG**, Johnson JR, Miller FW, Fox N, Matteson EL, Crowson CS, Gabriel SE. Do Solar Cycles Influence Giant Cell Arteritis and Rheumatoid Arthritis Incidence? *BMJ Open*. 2015 May 15;5(5): e006636. PMID: 25979866 PMCID: PMC4442155
91. Miller FW, Chen W, O'Hanlon TP, Cooper RG, Vencovsky J, **Rider LG**, Danko K, Wedderburn LR, Lundberg IE, Pachman LM, Reed AM, Ytterberg SR, Padyukov L, Selva-O'Callaghan A, Radstake T, Isenberg DA, Chinoy H, Ollier WER, Scheet P, Peng B, Lee A, Byun J, Lamb JA, Gregersen PK, Amos CI, with the Myositis Genetics Consortium. Genome-wide Association Study Identifies HLA 8.1 Ancestral Haplotype Alleles as Major Genetic Risk Factors for Myositis Phenotypes. *Genes and Immunity*. 2015 Oct;16(7):470-80. PMID: 26291516. PMCID: PMC4840953
92. Artlett CM, Sassi-Gaha S, Ramos R, Miller FW, **Rider LG**. Chimeric cells of maternal origin do not appear to be pathogenic in the juvenile idiopathic inflammatory myopathies. *Arthritis Research Therapy*, 2015 Sep 4;17(1):238. doi: 10.1186/s13075-015-0732-0. PMID: 26338728. PMCID: PMC4558637
93. Reed AM, Crowson CS, Hein M, de Padilla CL, Olazagasti JM, Aggarwal R, Ascherman DP, Levesque MC, Oddis CV; **RIM Study Group**. Biologic predictors of clinical improvement in rituximab-treated refractory myositis. *BMC Musculoskelet Disord*. 2015;16(1):257. PMID: 26382217. PMCID: PMC4574570
94. Gan L, O'Hanlon TP, Lai Z, Fannin R, Weller ML, Rider LG, Chiorini JA, Miller FW. Gene Expression Profiles from Disease Discordant Twins Suggest Shared Antiviral Pathways and Viral Exposures among Multiple Systemic Autoimmune Diseases. *PLoS One* 2015. Nov 10;10(11): e0142486. doi: 10.1371/journal.pone.0142486. eCollection 2015. PMID: 26556803 PMCID: PMC4640563

95. Yao L, Yip AL, Shrader JA, Volochayev R, Jansen AV, Miller FW, **Rider LG**. Validation of Quantitative Fat-Corrected and Conventional Muscle T2 Measurement in the Idiopathic Inflammatory Myopathies. *Rheumatology (Oxford)*. 2016 Mar;55(3):441-9. PMID: 26412808, PMCID pending
96. Rothwell S, Cooper RC, Lundberg IE, Miller FW, Gregersen PK, Bowes J, Vencovsky J, Danko K, Limaye V, Selva-O'Callaghan A, Hanna MG, Machado PM, Pachman LM, Reed AM, **Rider LG**, Cobb J, Platt H, Molberg O, Benveniste O, Mathiesen P, Radstake T, Doria A, De Bleecker J, De Paepe B, Maurer B, Ollier WE, Padyukov L, O'Hanlon TP, Lee A, Amos CI, Gieger C, Meitinger T, Winkelmann J, Wedderburn LR, Chinoy H, Lamb JA, and the Myositis Genetics Consortium. Dense Genotyping of Immune-Related Loci in the Idiopathic Inflammatory Myopathies Confirms HLA alleles as Strongest Genetic Risk Factor and Suggests Different Genetic Background for Major Clinical Subgroups. *Annals of Rheumatic Diseases*. *Annals of Rheumatic Diseases*, 2016 Aug;75(8):1558-66. PMID: 26362759, PMCID pending.
97. Habers GEA, Huber AM, Mamyrova G, Targoff IN, O'Hanlon TP, Adams S, Pandey JP, Boonacker C, van Brussel M, Miller FW, van Royen-Kerkhof A, **Rider LG**, for the Childhood Myositis Heterogeneity Study Group. Myositis autoantibodies, clinical features, and environmental exposures at illness onset are associated with disease course in juvenile myositis, *Arthritis and Rheumatology*, 2016, 68: 761-768. PMID: 26474155, PMCID PMC4767657
98. Lintner KE, \* Patwardhan A, \* Rider LG, Abdul-Aziz R, Wu YL, Lunstrom E, Padyukov L, Zhou B, Alhomosh A, Newsom D, White P, Jones KB, O'Hanlon TP, Miller FW, Spencer CH, Yu CY. Gene Copy-Number Variations (CNVs) of Complement C4 and C4A Deficiency in Genetic Risk and Pathogenesis of Juvenile Dermatomyositis. *Ann Rheum Dis*. 2016 Sep;75(9):1599-1606. PMID:26493816, PMCID pending.
99. van der Stap DKD, Rider LG, Alexanderson H, Huber AM, Gualano B, Gordon P, van der Net J, Mathiesen P, Johnson LG, Ernste FC, Feldman BM, Houghton KM, Singh-Grewal D, Garcia-Kutzbach A, Alemo Munters L, Takken T, on behalf of the International Myositis Assessment and Clinical Studies Group. Proposal for a candidate core-set of fitness and strength tests for patients with childhood or adult idiopathic inflammatory myopathies. *J Rheumatology*. *J Rheumatol*. 2016 Jan;43(1):169-176. PMID: 26568594 PMCID: PMC4698199
100. Nagaraju K, Ghimbovschi S, Rayavarapu S, Phadke A, Rider LG, Hoffman EP, Miller FW. Muscle type I interferon gene expression may predict therapeutic responses to rituximab in myositis patients. *Rheumatology (Oxford)*. 2016 *Rheumatology (Oxford)*. 2016 Sep;55(9):1673-80. PMID: 27215813, PMCID pending.
101. Parkes JE, Rothwell S, Day P, McHugh NJ, Betteridge ZE, Cooper RC, Ollier WE, Chinoy H, Lamb JA, and **Myositis Genetics Consortium (MYOGEN)**. Systematic protein-protein interaction and pathway analyses in the idiopathic inflammatory myopathies. *Arthritis Res Ther*. 2016 Jul 7;18(1):156. PMID: 27388770 PMCID: PMC4936183
102. Hong, K-M, Kim, H-K, Park, S-Y, Poojan, S, Kim, M-K, Joohon K, Tsao, B, Grossman, J, Rullo, OJ, Woo, J, McCurdy, DK, **Rider, L**, Miller, FW, Song, YW. CD3Z hypermethylation is associated with severe clinical manifestations in systemic lupus erythematosus and reduces CD3ζ chain expression in T cells. *Rheumatology*, 2016 Dec 10. pii: kew405. [Epub ahead of print]. PMID: 27940592 PMCID: pending
103. Kim S, Kahn P, Robinson AB, Lang B, Shulman A, Oberle EJ, Schikler K, Curran ML, Spencer C, **Rider LG**, and Huber AM, for the Juvenile Dermatomyositis Subcommittee of the Childhood Arthritis and Rheumatology Research Alliance. *Childhood Arthritis and Rheumatology Research Alliance*

consensus clinical treatment plans for juvenile dermatomyositis with skin predominant disease. *Pediatr Rheumatol Online J*. 2017 Jan 11;15(1):1. PMID: 28077146 PMCID: PMC5225591

104. Feldon M, Noroozi Farhadi P, Brunner HI, Itert L, Goldberg B, Faiq A, Wilkerson J, Rose KM, **Rider LG**, Miller FW\*, Giannini EH\* Predictors of Reduced Health-Related Quality of Life in Adult Patients with Idiopathic Inflammatory Myopathies. *Arthritis Care and Research*, 2017 Jan 24. doi: 10.1002/acr.23198. [Epub ahead of print]. PMID: 28118525. PMCID: pending \* contributed equally
105. Kishi T\*, **Rider LG\***, Pak K, Barillas-Arias L, Henrickson M, McCarthy PL, Shaham B, Weiss PF, Horkayne-Szakaly I, Targoff IN, Miller FW, Mammen AL, for the Childhood Myositis Heterogeneity Study Group. Anti-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Autoantibodies are Associated with DRB1\*07:01 and Severe Myositis in Pediatric Myositis Patients. *Arthritis Care and Research*, 2017, 2017 Jan 27. doi: 10.1002/acr.23113. [Epub ahead of print]. PMID: 28129483. PMCID: pending \* contributed equally
106. Aggarwal R\*, **Rider LG\***, Ruperto N, Bayat N, Erman B, Feldman BM, Oddis CV, Amato AA, Chinoy H, Cooper RG, Dastmalchi M, Fiorentino D, Isenberg D, Katz JD, Mammen A, de Visser M, Ytterberg SR, Lundberg IE, Chung L, Danko K, Garcia-De la Torre I, Song YW, Villa L, Rinaldi M, Rockette H, Lachenbruch PA, Miller FW\*\*, Vencovsky J\*\* for the International Myositis Assessment and Clinical Studies Group (IMACS) and the Paediatric Rheumatology Collaborative Study Group (PRINTO). 2016 American College of Rheumatology (ACR) - European League Against Rheumatism (EULAR) Criteria for Minimal, Moderate and Major Clinical Response for Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. *Arthritis and Rheumatology*, 2017, In press. PMID: pending. PMCID: pending \*, \*\* contributed equally
107. **Rider LG\***, Aggarwal R\*, Pistorio A, Bayat N, Erman B, Feldman BM, Huber AM, Cimaz R, Cuttica R, Knupp de Oliveira S, Lindsley C, Pilkington PA, Punaro M, Ravelli A, Reed AM, Rouster-Stevens K, van Royen A, Dressler F, Saad Magalhaes C, Constantin T, Davidson JE, Magnusson B, Russo R, Villa L, Rinaldi M, Rockette H, Lachenbruch PA, Miller FW, Vencovsky J\*\*, Ruperto N\*\* for the International Myositis Assessment and Clinical Studies Group (IMACS) and the Paediatric Rheumatology International Trials Organisation (PRINTO). *Arthritis and Rheumatology*, 2017, In press. PMID: pending. PMCID: pending \*, \*\* contributed equally
108. **Rider LG\***, Ruperto N\*, Pistorio A, Erman B, Bayat N, Lachenbruch PA, Rockette H, Feldman BM, Huber AM, Hansen P, Oddis CV, Lundberg IE, Amato AA, Chinoy H, Cooper RG, Chung L, Danko K, Fiorentino D, Garcia de la Torre I, Reed AM, Song YW, Cimaz R, Cuttica RJ, Pilkington CA, Martini A, van der Net J, Maillard S, Miller FW, Vencovsky J\*\*, Aggarwal R\*\*, for the International Myositis Assessment and Clinical Studies Group (IMACS) and the Paediatric Rheumatology International Trials Organisation (PRINTO). 2016 Development of Adult Dermatomyositis and Polymyositis and Juvenile Dermatomyositis Response Criteria—Methodological Aspects: An American College of Rheumatology/European League Against Rheumatism/International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. *Rheumatology*, 2017, In press. PMID: pending. PMCID: pending \*, \*\* contributed equally

#### Published Book Chapters, Review Articles or Editorials

1. **Rider, L.G.** and F.W. Miller. New perspectives on the idiopathic inflammatory myopathies of childhood. *Curr. Opin. Rheum.* 1994; 6:575-582. PMID: 7865376.

2. **Rider, L.G.** and F.W. Miller. Laboratory evaluation of the inflammatory myopathies. Clin. Diagn. Lab. Immunol. 1995; 2:1-9 (peer reviewed). PMID: 7719899. PMCID: PMC170091.
3. Plotz, P.H., **Rider, L.G.**, Targoff, I.N., Raben, N., O'Hanlon, T.P., and F.W. Miller. Myositis: Immunologic contributions to understanding causes, pathogenesis and therapy. Ann. Intern. Med. 1995; 122: 714-724 (peer reviewed). PMID: 7702234.
4. **Rider, L.G.** Assessment of disease activity and its sequelae in children and adults with myositis. Current Opin Rheumatology. 1996; 8:495-506. PMID: 9018452.
5. **Rider, L.G.** and F.W. Miller. Classification and treatment of juvenile idiopathic inflammatory myopathies. Rheum. Dis. Clin. N. Amer. 1997; 23:619-655. PMID:9287380.
6. **Rider, L.G.** and I.N. Targoff. Single organ systems and autoimmunity: Muscle Diseases. Textbook of Autoimmune Diseases, ed. R.G. Lahita, N. Chiorazzi, W.H. Reeves. Lipincott- Raven, Philadelphia, PA. 2000; pg 429 – 474.
7. **Rider, L.G.** and F.W. Miller. Idiopathic inflammatory muscle disease: Clinical aspects. Bailliere's Best Practice and Research: Clin. Rheumatol. 2000; 14:37 - 54. PMID: 10882213.
8. Shamim E, **L.G. Rider**, and F.W. Miller. Update on the genetics of the idiopathic inflammatory myopathies. Current Opinion Rheumatol. 2000; 12:482-91. PMID: 11092196.
9. Miller FW\*, **LG Rider\***, YL Chung, R Cooper, K Danko, V Farewell, I Lundberg, C Morrison, L Oakley, I Oakley, C Pilkington, J Vencovsky, K Vincent, DL Scott, DA Isenberg, for the International Myositis Outcome Assessment Collaborative Study Group. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology. 2001; 40: 1262-1273. \*These authors contributed equally. PMID: 11709610.
10. Barron KS, C Wallace, A Woolfrey, RM Laxer, M Horwitz, J Siegel, L Filipovich, N Wulffraat, M Passo, and **LG Rider**. Report on the National Institutes of Health workshop on autologous stem cell transplantation for pediatric rheumatic diseases. J Rheumatol. 2001; 28:2337-58. PMID: 11669179.
11. **Rider, L.G.** Outcome assessment in the adult and juvenile idiopathic inflammatory myopathies. Rheum. Disease Clin. N. Amer. 2002; 28: 935 – 977. PMID: 12506779.
12. **Rider, L.G.** Juvenile dermatomyositis (chapter 12.10). Rudolph's Pediatrics, 21<sup>st</sup> edition. CD Rudolph, AM Rudolph, eds. McGraw-Hill, NY. 2003; 853 – 856.
13. **Rider LG**, EH Giannini, M Harris-Love, G Joe, D Isenberg, C Pilkington, PA Lachenbruch, FW Miller, for the International Myositis Assessment and Clinical Studies (IMACS) Group. Defining clinical improvement in adult and juvenile myositis. J Rheumatol. 2003; 30: 603-617. PMID: 12610824.
14. **Rider, LG**. Calcinosis in Juvenile Dermatomyositis: Pathogenesis and Current Therapies. Pediatr Rheum On Line Jour 2003 1;2: <http://www.pedrheumononlinejournal.org/April/calinosi.html>. (peer reviewed)
15. N Ruperto, A Ravelli, KJ Murray, DJ Lovell, B Andersson-Gare, BM Feldman, S Garay, W Kuis, C Machado, L Pachman, AM Prieur, **LG Rider**, E Silverman, E Tsitsami, P Woo, EH Giannini, A Martini, for the PRINTO and the PRCSSG. Preliminary core set measures for disease activity and disease damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. Rheumatology, 2003;42: 1452-9. (peer reviewed) PMID: 12832713.

16. **Rider LG**, Pachman LM, Miller FW, Bollar H. Introduction. Myositis and You: A Guide to Juvenile Dermatomyositis for Patients, Families and Health Care Providers. 2007. The Myositis Association, Washington DC. Page 1 -8.
17. **Rider LG** and FW Miller. What is Juvenile Myositis? Myositis and You: A Guide to Juvenile Dermatomyositis for Patients, Families and Health Care Providers. 2007. The Myositis Association, Washington DC. Pages 9 - 22.
18. **Rider LG**, Pilkington C, Malleson P. Possible Medicines During the Course. Myositis and You: A Guide to Juvenile Dermatomyositis for Patients, Families and Health Care Providers. 2007, The Myositis Association, Washington DC. Pages 153 – 172.
19. **Rider LG**, Pilkington C, Ruperto N, Isenberg, D. Charting Your Child's Progress. Myositis and You: A Guide to Juvenile Dermatomyositis for Patients, Families and Health Care Providers. 2007, The Myositis Association, Washington DC. Pages 127- 138.
20. **Rider LG** and Pachman LM. Calcinosis. Myositis and You: A Guide to Juvenile Dermatomyositis for Patients, Families and Health Care Providers. 2007, The Myositis Association, Washington DC. Pages 231 - 240.
21. Rennebohm R, Feldman B, Huber A, Spencer C, Sundel R, and **Rider LG**. The clinical course and outcome of juvenile myositis. Myositis and You: A Guide to Juvenile Dermatomyositis for Patients, Families and Health Care Providers, 2007, The Myositis Association, Washington DC. pages 341 - 350.
22. Lachenbruch PA, Miller FW, **Rider LG**. Developing international consensus on measures of improvement for myositis. Statistical Methods in Medical Research, 2007, 1: 51 - 64. (peer reviewed). PMID: 17338294.
23. **Rider LG**. The heterogeneity of juvenile myositis. Autoimmunity Reviews. 2007; 6(4): 241-247. PMID: 17317616. PMCID: PMC1850932.
24. Mellins ED and **Rider LG**. Clinical research networks: a step towards evidence-based practice in pediatric rheumatology (editorial). Nature Clinical Practice Rheumatology. 2007; 3: 59. PMID: 17299440.
25. **Rider LG** and Miller FW. Pathology and pathogenesis of idiopathic inflammatory myopathies. Primer on the Rheumatic Diseases. Ed Klippel JH, Stone JH, Crofford LJ, White PH. Springer. 2007. Pg 368 - 374.
26. Yao L and **Rider LG**. Chapter 54: Idiopathic inflammatory myopathy. Imaging of the Musculoskeletal System, 1<sup>st</sup> Edition. TL Pope, HL Bloem, J Beltran, WB Morrison, DJ Wilson, editors. Elsevier. Philadelphia, PA. 2008. Pages 1171 – 1179.
27. Feldman BM, **Rider LG**, Reed AM, Pachman LM. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet. 2008; 371: 2201 – 2212. (peer reviewed). PMID: 18586175.
28. **Rider LG**, Leschek EW. Does early growth hormone therapy prevent glucocorticoid-associated growth retardation in children with JIA? Nature Clinical Practice Rheumatology. 2008; 4: 394-5. (peer reviewed). PMID: 18607398.
29. Dugan EM, Huber AM, Miller FW, and **Rider LG**, International Myositis Assessment and Clinical Studies Group. Photoessay of the idiopathic inflammatory myopathies. Dermatology Online Journal. 2009. 15 (2):1. PMID: 19336018. <http://dermatology-s10.cdlib.org/1502/reviews/photoessay/riderphotos.html>

30. Dugan EM, Huber AM, Miller FW, and **Rider LG**, International Myositis Assessment and Clinical Studies Group. Review of the cutaneous manifestations of the idiopathic inflammatory myopathies. *Dermatology Online Journal*. 2009. 15 (2): 2. PMID: 19336019.  
<http://dermatology-s10.cdlib.org/1502/reviews/photoessay/rideressay.html> (peer reviewed)
31. **Rider LG**. Outcomes and Assessment for Inflammatory Muscle Disease. Ed. Lawrence Kagen. *The Inflammatory Myopathies*. Humana Press, Springer, Dordrecht. 2009. Pages 253-276.
32. Reed AM, Pilkington CA, Feldman BM, Pachman LM, **Rider LG**. Juvenile Dermatomyositis. In: *A Clinician's Pearls & Myths in Rheumatology*. Ed. Stone JH. First edition. Springer (Dordrecht, Heidelberg, London, New York). 2009. Pages 201-210.
33. Wedderburn LR, **Rider LG**. Juvenile Dermatomyositis: New Developments in Pathogenesis, Assessment and Treatment. *Best Practice and Research Clinical Rheumatology*. 2009, 23: 655-678. PMID: 19853831. PMCID: PMC2774891.
34. **Rider LG**. Juvenile dermatomyositis. Section 15, Chapter 205. *Rudolph's Pediatrics*. 22<sup>nd</sup> edition. AM Rudolph, C Rudolph, L First, G Lister, AA Gershon, eds. McGraw-Hill, NY. 2010. Pages 15-27 to 15-31.
35. **Rider LG**, Lindsley C, Cassidy J. Chapter 24: Juvenile dermatomyositis. In *Textbook of Pediatric Rheumatology*, 6<sup>th</sup> edition, Ed Cassidy J, Petty R, Laxer R. Lindsley C. Saunders Elsevier. 2011. Pages 375-413.
36. **Rider LG** and Miller FW. Editorial: Mast Cells and Type I Interferon Responses in the Skin of Juvenile Dermatomyositis: Are Current Therapies Just Scratching the Surface? *Arthritis and Rheumatism*. 2010;62(9):2619-22. (editorial). PMID: 20506242. PMCID: PMC2946445.
37. **Rider LG** and Miller FW. Deciphering the clinical presentations, pathogenesis and treatment of the Idiopathic Inflammatory Myopathies. *JAMA*. 2011. 305: 183-190. (peer reviewed) PMID: 21224460. PMCID: PMC4047218
38. **Rider LG**, Werth VP, Huber AM, Alexanderson H, Rao AP, Ruperto N, Herbelin L, Barohn R, Isenberg D, Miller FW. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), Physician Global Damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI). *Arthritis Care and Research*. 2011 Nov;63 Suppl 11:S118-S157. PMID: 22588740. PMCID: PMC3748930
39. Yao L and **Rider LG**. Chapter 55: Idiopathic inflammatory myopathy. *Imaging of the Musculoskeletal System*, 2nd Edition. TL Pope, HL Bloem, J Beltran, WB Morrison, DJ Wilson, editors. Elsevier. Philadelphia, PA. 2012, Pages 1171 – 1179.
40. **Rider LG**, Katz J, Jones OY. Developments in the classification and treatment of the juvenile idiopathic inflammatory myopathies. *Rheumatic Disease Clinics of North America*. 2013 Nov;39(4):877-904. PMID: 24182859. PMCID: PMC3817412.

41. **Rider LG**, Danko K, Miller FW. Myositis Registries and Biorepositories: Powerful Tools to Advance Clinical, Epidemiologic and Pathogenic Research. *Current Opinion in Rheumatology*. 2014; 26:724-41. PMID: 25225838. PMCID: PMC5081267
42. Hoeltzel MF, Oberle EJ, Robinson AB, Agarwal A, Rider LG. The presentation, assessment, pathogenesis, and treatment of calcinosis in juvenile dermatomyositis. *Curr Rheumatol Rep*. 2014; 16:467. PMID: 25366934 PMCID: PMC5118224
43. Rider LG, Lindsley C, Miller FW. Chapter 26: Juvenile dermatomyositis. In *Textbook of Pediatric Rheumatology*, 7th edition, Ed Petty R, Laxer R. Lindsley C, Wedderburn L. Saunders Elsevier. 2015. pages 351-384.
44. Rider LG, Nistala K. The Juvenile Idiopathic Inflammatory Myopathies: An Update on Their Pathogenesis, Clinical and Autoantibody Phenotypes, and Outcomes. *Journal of Internal Medicine*, 2016 Jul;280(1):24-38. PMID: 27028907
45. Benveniste O, Rider LG, ENMC Myositis Outcomes Study Group. 213th ENMC International workshop: Outcome measures and clinical trial readiness in idiopathic inflammatory myopathies, 18-20 September 2015, Neuromuscular Disorders. 2016 Aug;26(8):523-34. PMID: 27312023
46. Sanner H and Rider LG. Long-term Outcomes in Juvenile Idiopathic Inflammatory Myopathies. CHAPTER 48, "The Myositis Handbook: An Inclusive Guide to the Inflammatory Myopathies." Ed Christopher-Stine L and Lundberg IE. 2016. In press.
47. Rider LG and Miller FW. Chapter 15. Outcome Assessment in the Idiopathic Inflammatory Myopathies. In *Myositis (Oxford Rheumatology Library)*, edited by Hector Chinoy and Robert Cooper, 2016, In press.
48. Rider LG. Chapter 205: Juvenile Dermatomyositis. MW Kline, S Blaney, AP Giardino, JS Orange, DJ Penny, GE Schutze, LS Shekerdemian, eds. McGraw-Hill, NY. 2016, In press.

## Books

**Rider LG**, Pachman LM, Miller FW and Bollar H, editors. Myositis and You: A Guide to Juvenile Dermatomyositis for Patients, Families and Health Care Providers. 2007. The Myositis Association. Washington DC.

## Letters and Photographs

1. **Rider LG**, PM Mendelman, J French, and DD Sherry. Group A streptococcal infection and Kawasaki syndrome. *Lancet* 1991; 337:1100-1101. PMID: 1673524.
2. Miller, FW, **Rider LG**, Plotz PH, Isenberg DA, Oddis CV. Diagnostic criteria for polymyositis and dermatomyositis. *Lancet* 2003; 362:1762-1763. PMID: 14643132.
3. Miller FW, **Rider LG**, Plotz PH, Rutkove SB, Pestronk A, Wortmann RL, Lundberg IE, Argov Z, Isenberg DA, Lacomis D, Oddis CV. Polymyositis: An overdiagnosed entity. *Neurology*. 2004; 63:402. PMID: 15277657.
4. Huber AM, Miller FW, **Rider LG**. Childhood Myositis Assessment Scale and muscle strength testing in patients with juvenile dermatomyositis: comment on the article by Huber et al – Reply. *Arthritis and Rheumatism* 2005; 52: 368-369

5. **Rider LG**, Miller FW, Lachenbruch PA, Isenberg D. Applicability of the Paediatric Rheumatology International Organisation disease activity core set for juvenile dermatomyositis: comment on the article by Ruperto et. al. 2008. Arthritis and Rheumatism (Arthritis Care and Research). 2008; 59: 1197-1198. PMID: 18668578.
6. **Rider LG**, Atkinson JC. Gingival and periungual vasculopathy of juvenile dermatomyositis. New England Journal of Medicine. Images in Clinical Medicine. 2009. 360 (15): e21. PMID: 19357401. PMCID: PMC2802054.
7. Huber AM, Lovell DJ, Pilkington CA, Rennebohm RM, **Rider LG**. Confusion concerning multiple versions of the Childhood Myositis Assessment Scale. Arthritis Care and Research. 2013; 66: 648. PMID:24285368.

## Government Publications

Guidance for Industry: Clinical Development Programs of Drugs, Devices, and Biological Products for the Treatment of Rheumatoid Arthritis. Food and Drug Administration, February 1999. <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071579.pdf>.

## Internet Sites

<http://www.niehs.nih.gov/research/resources/collab/imacs/main.cfm>  
 (see also <https://dir-apps.niehs.nih.gov/imacs/home.htm>)

## Multimedia

Award video for 2016 PhRMA Research and Hope Awards. [https://youtu.be/llhTARJkh\\_I](https://youtu.be/llhTARJkh_I)

Brief career biography video- released to Lab TV and NIH You Tube, National Institutes of Health, 2015  
<http://www.nih.gov/health-information/nih-clinical-research-trials-you/researcher-stories-why-we-became-scientists> at [www.LabTV.com](http://www.LabTV.com)

Juvenile Myositis: Information for Newly Diagnosed Families. Cure JM Foundation, 2010. (DVD)  
<http://www.youtube.com/watch?v=4cGDM99LTqQ&feature=youtu.be>

## SELECTED INVITED LECTURES AND PRESENTATIONS

- “Juvenile Myositis”, Myositis Workshop 2017, Tokyo, Japan, October 21, 2017
- Pediatric Grand Rounds on Juvenile Dermatomyositis, Suzanne Bowyer Memorial Lectureship, Riley Hospital for Children at Indiana University Health, September 13, 2017
- Meet the Professor Roundtable on Juvenile Dermatomyositis, American College of Rheumatology Pediatric Rheumatology Symposium (PRYSM), Houston, TX, May 17-20, 2017
- “Current Adult and Juvenile Myositis Repositories” and Lead Moderator, Research Directions in Juvenile Myositis”, The Second Global Conference on Myositis, Potomac, MD, May 5-8, 2017
- “Juvenile Myositis Phenotypes”, 8<sup>th</sup> Annual Pediatric Rheumatology: An Update for Clinicians, NYU School of Medicine, New York, NY, March 15, 2017
- “Biologic Therapies for Juvenile Myositis”, Juvenile Myositis: A 2017 Update on Care and Research, Dell Children’s Hospital, February 17, 2017, and Cure JM Annual conference, February 18, 2017, Austin, TX
- “Juvenile Myositis - Tales from the Other Side of JIA”, Dr. Carol Wallace Juvenile Arthritis Research Symposium, Seattle Children’s, May 14, 2016, Seattle WA
- “Myositis Response Criteria, NIH Studies of Calcinosis and Other Myositis Updates”, CARRA annual meeting, Toronto, Canada, April 16, 2016
- “Myositis Activity Assessment Using IMACS Core Set Measures”, Idera Pharmaceuticals Investigator meeting, January 23, 2016, remotely to Florida

“Research Updates from the NIH and GWU Myositis Center”, Cure JM Family Conference, January 16, 2016, St Petersburg, FL

“The New Classification and Response Criteria for Juvenile Dermatomyositis”, Juvenile Myositis: A 2016 Update on care and Research, Johns Hopkins All Children’s Hospital, St Petersburg, FL, January 15, 2016

“How to Apply the New Response Criteria for Juvenile Dermatomyositis in Clinic and Research”, American College of Rheumatology meeting, San Francisco, CA, November 11, 2015

“Polymyositis and Dermatomyositis- Adult and Pediatric”, ARHP Clinical Focus Course- Clinical Advances in Rheumatic Diseases, A Case-Based Approach. American College of Rheumatology meeting, November 7, 2015, San Francisco, CA.

“IMACS System: Past History, Validation and Publications”, “IMACS Core Set Measures for Muscle Weakness and Functional Disability”, and “Myositis Activity Assessment Tool and Myositis Damage Assessment”, and co-organizer, 213<sup>th</sup>, ENMC Workshop: Outcome measures and clinical trial readiness in Idiopathic Inflammatory Myopathies (IIM), Heemskerk, The Netherlands, September 18-20, 2015

“Clinical and Autoantibody Phenotypes of Juvenile Myositis and Associated Outcomes”, and “Improvement Criteria for Adult and Juvenile Myositis: Background on Methodology”, and Steering Committee member, First International Conference on Myositis, Stockholm, Sweden, May 8-11, 2015

Invited participant, international consensus conference on developing internationally agreed minimal dataset for juvenile dermatomyositis. Liverpool, England, March 22-24, 2015

“Clinical and Autoantibody Phenotypes of Juvenile Myositis”, American College of Rheumatology meeting, Boston, MA, November 17, 2014

“Assessment of JDM”, Juvenile Myositis: A 2014 Update on Care and Research: Cure JM Medical Conference, Stanford University, October 3, 2014

“Toward a Better Understanding of Adult and Juvenile Myositis: Phenotype, Phenotype, Phenotype”. Invited keynote speaker, University of Pennsylvania Rheumatology Research Training Day, Philadelphia, PA, June 17, 2014

Meeting organizer, co-lead Pediatric Working Group, and speaker at International Consensus Conference to Develop Improvement Criteria for Juvenile Dermatomyositis and Adult Dermatomyositis and Polymyositis”, Paris France: “Prior Approaches: IMACS Core Set Measures and Preliminary Definitions of Improvement for Adult DM/PM and Juvenile Dermatomyositis”, “Development of New Definitions of Improvement for Myositis: Background on the Current Project”, “Presentation of Top Performing Newly Developed Definitions of Minimal Clinical Improvement and Moderate and Major Clinical Response”, “Combined Group Discussion of Results/Problem Areas from the Workshop, and Future Plans” Paris, France, June 9-10, 2014

“IMACS Activity and Damage Measures” and “International Myositis Collaboration”, Invited keynote speaker, Canadian Inflammatory Myopathy Consortium meeting, Montreal, Canada, May 16, 2014

“The Phenotypes of the Idiopathic Inflammatory Myopathies”, Medicine Grand Rounds, Washington Hospital Center, Washington DC, April 9, 2014

Meet the Professor Roundtable on Juvenile Dermatomyositis, ACR Pediatric Rheumatology Symposium (PRYSM), Orlando, FL, April 5, 2014

“International Myositis Classification Criteria for Adult and Juvenile Myositis” and “ACR-EULAR Myositis Response Criteria Project”, CARRA meeting, Orlando, FL, April 2, 2014

“Unraveling the Mysteries of Genes and the Environment in Children with Myositis”, NIEHS DIR Council, Bethesda, MD, February 11, 2014

“Myositis Phenotypes and the Environmental Connection”, Autoimmune Disease Network Symposium, University of Calgary, Alberta, Canada, January 31, 2014

“Assessment and Treatment of Juvenile Myositis”, Calgary Children’s Hospital, Alberta, Canada January 31, 2014.

“Physical Therapy for Juvenile Myositis”, Cure JM Conference, Chicago, IL, July 20, 2013

“Heterogeneity of Juvenile Myositis”, Cure JM Medical Conference, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, July 19, 2013

“International Myositis Classification Criteria for Adult and Juvenile Myositis” and “ACR-EULAR Myositis Response Criteria Project”, CARRA meeting, April 21, 2013, Chicago, IL

“The Clinical and Autoantibody Phenotypes of Juvenile Myositis” and “Focus on Disease Diagnostics: Muscle Strength and CMAS Testing”, Cure JM Conference, Baltimore, MD, October 12-13, 2012

“Clinical Presentations and Diagnosis of Juvenile Myositis”, Cure JM Health Professions Meeting, Johns Hopkins University, Baltimore, MD, October 11, 2012 (and Expert for Educational Forum on Juvenile Myositis)

“Myopathies: from Bedside to Bench”, “Meet the Professor: Treatment of juvenile inflammatory myopathies” and Lecture: “Treatment of Severe Juvenile Dermatomyositis”, XXIX Brazilian Congress of Rheumatology, Vitoria, Brazil, September 20-22, 2012

“Adult and Juvenile Idiopathic Inflammatory Myopathies”, Department of Medicine Grand Rounds, George Washington University, Washington, DC, May 31, 2012

Congressional Briefing: “Environmental Factors in Autoimmune Disease” as part of “Multi-Generational Impact of Autoimmune Disease: America’s Silent Health Crisis”, Rayburn Building, Washington DC, March 28, 2012

“How to Assess and Treat Myositis”, Excellence in Rheumatology meeting, Madrid, Spain, January 27, 2012

Congressional Briefing, “Environmental Factors in Pediatric Autoimmune Diseases”, as part of Children’s Environmental Health briefing, Capitol Visitor’s Center, Washington DC, October 27, 2011

“JM News from the NIH: Genetic and Environmental Studies”, Cure JM Conference, Seattle, WA June 24, 2011

“Juvenile Myositis: From Seattle’s Bedside to Bethesda”. Pediatric Grand Rounds, Children’s Hospital and Medical Center, Seattle, WA. June 23, 2011. (and Expert for Educational Forum on Juvenile Myositis)

“Cutaneous Assessment Tools for Dermatomyositis”, “International Myositis Classification Criteria Project”, “NIEHS Twin Sibling Study”, “TMA’s MYOVISION Registry”. CARRA meeting (JDM Working Group), Miami, FL, June 1-2, 2011

“Juvenile Myositis: A Clinical and Research Update”, Pediatric Grand Rounds, Hackensack University Medical Center, Hackensack, NJ, May 12, 2011

“Practice Potpourri: What should I tell my patient with polymyositis who wants to exercise and lift weights?” American Rheumatology Health Professionals, Atlanta, GA, and “Making the Most of Your Fellowship Training”, American College of Rheumatology Fellows-in-Training mentoring session, Atlanta, GA, November 2010

“Myositis Autoantibody Phenotypes and the Environmental Connection”, Pediatric Rheumatology European Society, Valencia, Spain, September 11, 2011

“Juvenile Dermatomyositis: A Research Update”, Pediatric Grand Rounds, Uniformed Services University of the Health Sciences, Bethesda, MD, April 8, 2010

“Phenotypes as Clues to Deciphering the Pathogenesis and Treatment of Myositis”, NIH Clinical Center Grand Rounds, Bethesda, MD, February 24, 2010

Invited participant, Educational Forum, “Potential Complications of Juvenile Myositis” and “Research Update from NIH: Genetic and Environmental Factors”, Cure JM Foundation. Austin, TX, February 13, 2010

Rheumatism Society of Houston, Invited Lecture, and Grand Rounds, University of Texas at Houston, Houston, TX, August 24, 2009

Rheumatology Grand Rounds, Georgetown University Medical Center June 16, 2009

Invited participant and co-chair, Research opportunities breakout session, Food and Drug Administration Public Workshop on Developing a Consolidated Pediatric Rheumatology Observational Registry, Silver Spring, MD May 12-13, 2009

“Clinical Databases: Setup and Maintenance for Clinical Data Sharing”, NIAMS Conference on SAPHO/Bechet’s, Bethesda, MD, September 4, 2008

“Adult and Juvenile Myositis”, George Washington University Rheumatology lecture series, July 18, 2008; August 7, 2009

“Components and Predictors of Damage in Juvenile Myositis Using the Myositis Damage Index”, American College of Rheumatology Pediatric Rheumatology Meeting, Keystone, CO, March 4, 2008

Invited Participant, CARRA Consensus Conference to Develop Treatment Protocols for Juvenile Dermatomyositis, Toronto, Canada, November 30 – December 2, 2007

Department of Pediatrics Grand Rounds, Children’s Memorial Hospital, Northwestern University School of

Medicine, "Juvenile Myositis: A Research Perspective", Chicago, IL, November 16, 2007

"Rheumatic Disease Update: Adult and Juvenile Dermatomyositis/Polymyositis", American Rheumatology Health Professionals, Boston, MA, November 10, 2007

Cure JM Foundation Educational Forum and Panel Discussion, "Juvenile Myositis: Assessing Outcomes and Potential New Therapies", Arlington, VA, October 27, 2007

Department of Pediatrics Grand Rounds, Georgetown University School of Medicine, "Juvenile Myositis: A Clinical Update", Washington DC, May 11, 2007

Rheumatology Grand Rounds, George Washington University School of Medicine, "Juvenile Myositis", Washington DC, March 29, 2007

Faculty member, Clinical Immunology Society School for Autoimmune Diseases, "Immunogenetic and Environmental Risk Factors for Juvenile Myositis". Santa Fe, New Mexico, March 14 -18, 2007

"IMACS Clinical Data Repository" and Chair, IMACS/JDM Working Group Breakfast Meeting, November 14, 2006

American College of Rheumatology, Pediatric Study Section, "Immunogenetic and Environmental Risk Factors for Juvenile Myositis", Washington DC, November 13, 2006

Rheumatology Grand Rounds, Georgetown University School of Medicine, "Juvenile Myositis", Washington DC, October 25, 2006

Ann Hengel Lecture in Pediatric Rheumatology. "Juvenile Dermatomyositis" Medical College of Wisconsin, Milwaukee, Wisconsin. April 28, 2006.

Clinical Immunology Society School for Autoimmune Diseases, "Juvenile Myositis". Faculty, Santa Fe, New Mexico, March 15 -18, 2006,

Invited Alumni Panelist, "Medicine and Research", Duke University Career Week, Durham, NC, January 28, 2006.

American Academy of Pediatrics Workshop, "Juvenile Dermatomyositis Dilemmas: A Case of Flare Following Remission". San Diego, CA, November 15, 2005.

Meeting co-organizer and presentation of "IMACS Internet Site" and "IMACS Outcomes Repository", San Diego, CA November 13, 200,

Rituximab in Myositis Investigator's Meeting, "Core Set Measures, including the MMT8, and the Definition of Improvement", and "Rituximab in Myositis Study Protocol" October 29, 2005 and February 6, 2006, Bethesda, MD.

The Myositis Association Annual Conference. Medical Panel: "TMA's Research Program and Funded Research on Juvenile Myositis" and Workshop on "Juvenile Myositis", October 8, 2005, Cleveland, OH.

American Juvenile Arthritis Organization National Conference. "Juvenile Dermatomyositis" Workshop and Roundtable Discussion, Providence, RI, July 29, 2005.

Rheumatology Grand Rounds, University of Pittsburgh, Pittsburgh, PA. November 12, 2004.

"Classification of Juvenile Myositis", Working Group meeting on the Classification of Idiopathic Inflammatory Myopathies, October 26, 2004, Bethesda, MD; Meeting co-organizer for Working Committee meeting, Dulles Airport, VA, November 11, 2005.

"Juvenile Myositis Handbook", The Myositis Association, Conference on Juvenile Myositis, May 9, 2004, Bethesda, MD.

Rheumatology Grand Rounds, Hospital for Special Surgery, Cornell Medical College, NY, NY, February 11, 2004

Invited Alumni Panelist, Duke University Career Week, Durham, NC, January 31, 2004 (sessions on Science and Research, Women and Leadership).

"Meet the Professor: Juvenile Dermatomyositis", American College of Rheumatology meeting, November 12/13, 2001, San Francisco, CA; October 26/27, 2002, New Orleans, LA; October 27-29, 2003; Orlando, FL; October 25/27, 2003, Orlando, FL.

Meeting Co-Organizer and Presentation of several papers ("Summary of IMACS Definitions of Improvement", "Future Plans for IMACS" Workshop"), IMACS Meeting, October 27, 2003, Orlando, FL.

Invited Participant and Speaker, Pediatric Rheumatology International Trials Organization (PRINTO) International Consensus Conference on Defining Improvement in Juvenile Dermatomyositis. "IMACS Preliminary Definitions of Improvement for Juvenile and Adult Myositis". September 29 – 30, 2003, Camogli,

Italy.

European League Against Rheumatism (EULAR) meeting, “Preliminary Definitions of Improvement for Adult and Juvenile Myositis” and moderated session on Difficult Cases of Myositis/Myopathies, June 20, 2003, Lisbon, Portugal

Schlager Family Visiting Professor Lectureship in Juvenile Dermatomyositis April 30, 2003, Children’s Hospital, Boston, MA:” Juvenile Idiopathic Inflammatory Myopathies: Lessons from the Children”.

Rheumatology Grand Rounds, Brigham and Women’s Hospital: Evaluation and Treatment of the Juvenile Idiopathic Inflammatory Myopathies, April 29, 2003, Boston, MA.

American Academy of Pediatrics Pediatric Rheumatology 2003: Park City and Beyond: General Session, “Preliminary Definitions of Improvement for Juvenile and Adult Myositis” (March 26, 2003); Meet the Expert, “Juvenile Dermatomyositis” (March 23, 2003); Concurrent Session, “The Development of Outcome Measures for Juvenile Dermatomyositis” (March 23, 2003), Snowmass, CO.

American College of Rheumatology meeting, Clinical Symposium, “Treatment of Refractory Juvenile Dermatomyositis”, October 26, 2002, New Orleans, LA.

American College of Rheumatology meeting, October 29, 2002, New Orleans, LA: Presentation of 2 papers, “Extra muscular disease activity is frequent in adult and juvenile idiopathic inflammatory myopathies (IIM) and does not correlate with other myositis activity measures” and “Defining clinically relevant change in core set activity measures for adult and juvenile idiopathic inflammatory myopathies”

Meeting Co-Organizer and Presentation of several papers (“Summary of the First Workshop”, “Top Candidate Definitions of Improvement for Adult and Juvenile Myositis”, “Clinical Trial Design Issues”, “Preliminary Study of Disease Damage in Adult and Juvenile Myositis using the Myositis Damage Index”), 2<sup>nd</sup> Workshop, Developing Consensus on Outcomes and Clinical Trial Design Issues in Adult and Juvenile Myositis, October 22 – 23, 2002, New Orleans, LA.

The Myositis Association Annual Conference. Medical Panel: “Similarities and Differences between Adult and Juvenile Idiopathic Inflammatory Myopathies” and Workshop on “Juvenile Myositis”, September 28, 2002, Atlanta, GA.

“Scoring of the Cutaneous Manifestations of the MITAX and Myositis Damage Index”; Presentation of Sample Cases of Global Activity and Damage Ratings, and Myositis Workshop Participant in two Myositis Outcome Measure Workshops, London, England (May 2002, March 2001).

“New Developments in the Juvenile Idiopathic Inflammatory Myopathies”, Grand Rounds, Department of Pediatrics, Stanford University, Palo Alto, CA, November 16, 2001.

American College of Rheumatology meeting, November 13, 2001, San Francisco, CA: Presentation of paper, “Lipodystrophy in juvenile dermatomyositis is associated with calcinosis, but not with adipocyte differentiation factor *dIk* levels

Meeting Organizer and Presentation of several papers on Core Set Outcome Measures in Adult and Juvenile Myositis, for International Workshop on Myositis Outcome Measures and Clinical Trial Design Issues: Defining Improvement in Adult and Juvenile Myositis. November 9-10, 2001, Palace Hotel, San Francisco, CA.

“Assessment of Disease Activity and Damage in Juvenile Dermatomyositis (JDM)”, and Invited Participant, International Consensus Conference to Define Core Sets of Outcome Measures for Juvenile Systemic Lupus Erythematosus and Juvenile Dermatomyositis, March 30 – April 4, 2001, Pavia, Italy

“Acquired Lipodystrophy associated with Autoimmune Diseases”, First International Workshop on Lipodystrophic Diabetes and other syndromes of Lipodystrophy, March 23, 2001, Bethesda, MD.

NIAMS Intramural Research Program Workshop on Pediatric Rheumatic Diseases, “Juvenile Dermatomyositis: Future Research Needs”, February 16, 2001, Bethesda, MD.

Joseph L Hollander Lectureship, Division of Rheumatology, “Pathogenesis of Dermatomyositis and Polymyositis” and “Myositis-specific and Myositis-associated Autoantibodies in the Juvenile Idiopathic Inflammatory Myopathies”, The Children’s Hospital of Philadelphia and University of Pennsylvania, January 17, 2001, Philadelphia, PA.

American College of Rheumatology Pediatric Subsection Meeting. “Clinical and Serologic Classification of Juvenile Myositis”, October 30, 2000, Philadelphia, PA.

Myositis Association of America Annual Conference. Workshop on Juvenile Myositis. October 14, 2000,

Fairfax, VA.

FDA Arthritis Advisory Committee Presentation, Closed Session, Gaithersburg, MD, April 11, 2000.

NIAMS Workshop on Inflammatory Myopathies, April 5-6, 2000, Bethesda, MD: "Juvenile Myositis: Clinical Overview".

Workshop: Hands on Approach to the Diagnosis and Management of the Child with Rheumatic Disease: Juvenile Dermatomyositis. American Academy of Pediatrics meeting, Washington DC, October 10, 1999.

VI Pediatric Rheumatology European Congress/EULAR, Glasgow, Scotland, June 6, 1999: "Classification and epidemiology of the juvenile idiopathic inflammatory myopathies".

National Institutes of Health Clinical Center Grand Rounds, Bethesda, MD, May 27, 1999: "Lipodystrophy in Association with Autoimmune Disease" as part of Clinical Staff Conference: "The importance of Fat: Lipoatrophy, Insulin Resistance and Diabetes", S. Taylor, moderator.

Park City IV International Pediatric Rheumatology Meeting, Allied Health Professionals section, March 18, 1998, Park City, Utah, "Clinical Evaluation and Management of Childhood Myositis"

American Academy of Pediatrics, Rheumatology Subsection, November 2, 1997, New Orleans, LA: "The Spectrum of Childhood Inflammatory Myopathies"

FDA Arthritis Advisory Committee Meeting, February 4/5, 1997: "Juvenile Rheumatoid Arthritis and the Proposed Application of the Pediatric Use Regulation".

National Institutes of Health Clinical Center Grand Rounds, September 29, 1993; "Juvenile idiopathic inflammatory myopathies" as part of Clinical staff conference "Myositis: Immunologic contributions to understanding causes, therapy", P.H. Plotz, moderator.